Amino acid-n-carboxy anhydrides hvaing substituent at nitrogen

ABSTRACT

This invention provides amino acid N-carboxyanhydrides, each of which has an N-acyl substituent on its nitrogen atom, is represented by the following formula (1):  
                 
 
     readily reacts with nucleophilic reagents such as free amino acids, alcohols, anions or the like, and are intermediates useful for the high-yield production of amino acid derivatives, optically active compounds, peptides, polypeptides and the like useful in many fields lead by the fields of pharmaceuticals and agrochemicals, and also provides a process for the production of the amino acid N-carboxyanhydrides. Further, the present invention also provides a process for the production of diamides, which uses the compounds of the formula (1) and amine derivatives represented by the following formula (7):  
                 
 
     These diamides can also be suitably used for the production of amino acid derivatives, optically active compounds, peptides, polypeptides and the like.

TECHNICAL FIELD

[0001] This invention relates to activated amino acid derivatives which are important intermediates useful in many fields led by the fields of pharmaceuticals and agrochemicals. The present invention is also concerned with novel amino acid N-carboxyanhydrides each of which has a substituent of the N-acyl type on a nitrogen atom thereof, and also with a process for the production of diamides, which makes use of the amino acid N-carboxyanhydrides, requires fewer steps and is economical.

BACKGROUND ART

[0002] Amino acids are available rather readily at low prices and have diverse structures and asymmetric carbon atoms, so that they have been widely used for many years as raw materials or the like for a variety of optically active compounds led by peptides. In particular, production technology of peptides, which uses amino acids as raw materials, has been one of important basic technologies for many years in many fields led by the fields of pharmaceuticals and agrochemicals. Keeping in step with the advance of molecular biology in recent years, the importance of peptides tends to increase progressively. There is, accordingly, an outstanding demand for an economical production process of peptides, which is suited for industrial practice on large scale.

[0003] The principle of peptide production resides a reaction in which a carboxyl group of an amino acid and an amino group of an amine derivative, which may be an amino acid, are subjected to dehydrating condensation to form an amide bond. In practice, however, a free amino acid becomes an ampholytic ion, forms an internal salt and is stabilized, so that the above-mentioned reaction does not occur spontaneously. Even if the reaction should proceed, high-yield production of a specific target product cannot be expected because the amino groups contained in the respective reactants are free and many dipeptides, diketopiperazine derivatives and the like are hence byproduced.

[0004] To obtain the target peptide with good yield, functional groups other than those needed have to be masked beforehand to prevent occurrence of undesired reactions. In the case of a methyl ester or the like, its reaction velocity is low and impractical so that a carboxyl component must be activated suitably. A protecting group used as a mask not only plays a role to prevent a side reaction but also has an effect to reduce the polarity of the amino acid and to render it more readily soluble in an organic solvent.

[0005] Examples of the protecting group can include urethane-type protecting groups such as tert-butoxycarbonyl (Boc) group and benzyloxycarbonyl (Z) group, alkyl-type protecting groups such as trityl group, and acyl-type protecting groups such as formyl group, tosyl group, acetyl group and benzoyl group. In these protecting groups, urethane-type protecting groups can hardly induce racemization [Jiro Yajima, Yuki Gosei Kyokai Shi (Journal of Synthetic Organic Chemistry, Japan), 29, 27 (1971); Noboru Yanaihara, Pharmacia, 7, 721 (1972)], but acyl-type and alkyl-type protecting groups are accompanied by a drawback that they tend to induce racemization. Further, alkyl-type protecting groups do not fully mask the basicity of an amino group so that the amino group may still be subjected to further acylation. With a trityl group, no second acylation can take place owing to its steric hindrance. Conversely, this steric hindrance makes it difficult to achieve introduction itself of a trityl group, and further, it is not easy to conduct a condensation reaction between a trityl-protected amino acid with and a trityl-protected amine.

[0006] A synthesis process which includes introduction of protecting groups requires protecting and deprotecting steps, each of which requires a costly reagent, and also purification steps after the protecting and deprotecting groups, respectively. This synthesis process, therefore, results in multi-step production, leading to an increase in cost.

[0007] If it is difficult to allow a condensation reaction to proceed easily between an amino acid and an amine, there are processes in each of which a carboxyl group of an amino acid derivative with a protected amino group is activated by an electron-attracting substituent to facilitate its nucleophilic attack on the carbon atom of a carbonyl group of the amine. Illustrative of these processes are the acid chloride process in which an activated amino acid is derived using PCl₅, PCl₃ or thionyl chloride, the azidation process in which an activated amino acid is derived from an amino acid ester or the like via a hydrazide, the mixed acid anhydride process in which an activated amino acid is derived from a protected amino acid and another acid, and the crosslinking process making use of a conventional condensing agent such as N,N′-dicyclohexylcarbodiimide (DCC) or 1,1-carbonyl-diimidazole (hereinafter abbreviated as “CDI”). However, the acid chloride process involves a problem that many side reactions occur, the azidation process is accompanied by a problem that the derivation into an azide is very cumbersome, and the mixed acid anhydride process has a problem that disproportionation tends to occur when the temperature rises (“Peptide Synthesis” written by Nobuo Izumiya et al.). The process making use of a condensing agent is also accompanied by some drawbacks. In the case of DCC, for example, an acylisourea which is an intermediate formed by a reaction between a carboxyl group and DCC may undergo an intermolecular rearrangement in the presence of a base to form an acylurea, thereby lowering the yield of the target product or making it difficult to separate the acylurea from the target product. Further, DCC dehydrates the co-amide of asparagine or glutamine to form a nitrile. On the other hand, CDI is an expensive reagent, and the crosslinking process making use of CDI is not considered to be an economical production process of peptides.

[0008] As described above, many peptide production processes have been studied. To be industrially stable production technology or low-cost production technology, however, these processes have to be considered to be still insufficient.

[0009] On the other hand, amino acid N-carboxyanhydrides (referred to as “NCAs” when abbreviated) which have been studied as active amino acids readily react with most free amines. Primary merits of NCAs include that they themselves are effective acylating agents (“Peptides”, 9, 83) and that they permit more economical production through fewer steps than the commonly-employed crosslinking process making use of a condensing agent such as N,N-dicyclohexylcarbodiimide or 1,1-carbonyldiimidazole or the N-hydroxysuccinimide ester crosslinking process. In addition, these amino acid NCAs do not develop the problem of racemization or the like of amino acids under reaction conditions commonly employed for the production of peptides. NCAs have, therefore, been expected for many years to serve as important intermediates for the synthesis of peptides [Pheiol Chem., 147, 91 (1926)].

[0010] The peptide synthesis which uses an N-unsubstituted NCA as a production intermediate and has been known well for many years, however, involves many problems in that side reactions such as a polymerization reaction are always hardly controllable and the reactivity and stability differ depending on the kinds of the reactants. This peptide synthesis, therefore, has not been considered as a common peptide production process although its potential utility has been recognized. With a view to solving these problems, numerous improvements have been made. For example, Bailey et al. reported an illustrative condensation reaction between L-alanine-NCA and glycine under low temperature (−40° C.) conditions in an organic solvent [J. Chem. Soc., 8461 (1950)]. Further, Robert G. D. et al. reported illustrative production of a dipeptide under 0 to 5° C. conditions in an aqueous solution (around pH 10) by using L-phenylalaline-NCA [J. Am. Chem. Soc., 88, 3163 (1966)]. In addition, Thomas J. B. et al. reported potential industrial utility of a condensation reaction making use of L-alanine-NCA and L-proline [J. Org. Chem., 53, 836 (1988)].

[0011] Despite these efforts, however, N-unsubstituted NCAs are very limited in conditions optimal for the prevention of a polymerization reaction and racemization reaction as side reactions and are not suited from the industrial viewpoint.

[0012] Accordingly, efforts have been made in attempts to solve problems in polymerization control and the like by introducing a substituent of the N-alkyl or N-sulfenyl type onto a nitrogen atom of an NCA. Reported in patents and other technical publications include, for example, N-methyl-NCA, N-ethyl-NCA, N-nitrophenylsulfenyl-NCA [Kricheldorf et al., Angew. Chem. Acta 85, (1978) 86], N-xanthyl-NCA [Halstroem and Kovacs et al., Acta Chemica Scandvnavia, Ser. B, 1986, BYO(6), 462; U.S. Pat. No. 4,267,344], and N-trityl-NCA (Block and Cox et al., “Peptides, Proc. of the 5^(th) Europ. Symp., Oxford, September 1962, Pergramon Press 1963, Compiled by G. T. Young, page 84”. However, production processes of these compounds themselves lack general applicability, and effects of these compounds for polymerization control and the like are not sufficient. These compounds, therefore, have not lead to solution of the fundamental problems.

[0013] In 1980's, it was attempted to control the reactivity of an NCA by introducing a trimethylsilyl group onto the nitrogen atom of the NCA. This control was practiced with glycine-NCA (Bayer AG, DE 1768871). This approach indicated possibility of suppressing a polymerization reaction which was considered to be one of serious side reactions, but involves a problem in stability and a problem of an increase in production cost, and its application to other amino acids has not been made since then. The idea of introducing a substituent onto a nitrogen atom was subsequently applied by Palomo C. et al. to a condensation reaction between a non-natural amino acid and an amine by using a NCA in which a nitrogen atom is protected by a benzyl group [Chem. Commun., 7, 691 (1997); Tetrahedron Lett., 38(17), 3093 (1997)]. However, these processes are also accompanied by problems in that the target NCA cannot be produced economically due to the need for many steps for its synthesis and a limitation is imposed on amino acids which can be synthesized.

[0014] In recent years, N-substituted NCAs with substituents of the urethane type as substituents on nitrogen atoms were reported. Firstly, Kricheldolf et al. reported a process for the production of N-methoxycarbonylglycine-NCA and N-ethoxycarbonylglycine-NCA [Macromol. Chem., 178, 905 (1977)]. Then, Fuller et al. reported production of N-urethane-substituted NCA and N-urethane-substituted thiocarboxylic acid anhydride from amino acids other than glycine (Bioresearch Inc., JP 2875834 B). They admirably solved the problem of polymerization control or the like by using these N-urethane-substituted NCAs. They, however, used costly N-urethane groups as amino-protecting groups, thereby failing to make good use of the merit of NCAs that amide compounds can be produced through fewer steps at low cost without using protecting groups. Further, they did not conduct any study on N-substituted NCAs other than N-urethane-substituted NCAs and made no mention about N-acyl-substituted NCAs.

[0015] An N-acyl-substituted NCA, on the other hand, is expected to provide a short and economical process for forming an amino acid into a derivative thereof because use of a target amide structure as a substituent in NCA prevents side reactions such as polymerization and obviates protection and deprotection. For example, a reaction with a desired amine has possibility of synthesizing a diamide compound at low cost without steps such as bonding and elimination of a protecting group to and from an amino group.

[0016] Only an extremely limited number of reports have, however, been made on the synthesis of N-acyl-substituted NCAs. Moreover, none of these synthesis processes are equipped with general applicability. For example, Kricheldolf et al. reported 3-(3,5-dinitrobenzoyl)-4,4-dimethyl-2,5-oxazolinedinedione in the article referred to in the above [Macromol. Chem., 178, 905 (1977)]. This is the only example reported by them concerning N-acyl-substituted NCAs. In addition, the amino acid employed in their report is di-substituted at the a-position and contains no asymmetric carbon atom, and their report does not disclose any N-acyl-substituted NCA with other acyl group. Accordingly, their process is poor in wide applicability.

[0017] N-(3-oxobutanoyl)-substituted NCAs, on the other hand, are reported in JP 48-86886 A. The substituent on the nitrogen atom is, however, limited only to an N-(3-oxobutanoyl) group introduced using a diketene in their production process, so that this process cannot introduce acyl groups which are widely used. Concerning the compounds represented by the formula (2) and the formula (3), respectively, no synthesis process is disclosed [M. Wakselman et al., Amino Acids, 7, 67-77 (1994); Reibel Leonard et al., Bull. Soc. Chim. Fr., 3, 1025-319 (1972)]. These articles disclose only the structures of such compounds, and therefore, no synthesis is feasible following the articles.

[0018] As described above, many of conventional reports are directed to alkyl- or urethane-substituted NCAs, and production and use of N-acyl-substituted NCAs are still considered to be very difficult or impossible although they are expected to have high utility [“Peptides, Proc. of the 5^(th) Europ. Symp., Oxford, September 1962”, Pergamon Press 1963, Compiled by G. T. Young, Pages 84-87; Yonezawa et al., “Yuki Gosei Kagaku (Synthetic Organic Chemistry)”, 47(9), 782-794 (1989)].

[0019] In short, N-acyl-substituted NCAs and various amino acid derivatives produced by amidation reactions making use of these NCAs are expected to find utility as useful compounds or production processes in many fields led by the fields of pharmaceuticals and agrochemicals. Nonetheless, neither commonly applicable production process of N-acyl-substituted NCAs nor widely applicable, industrially-excellent peptide production process making use of these NCAs were known practically to date.

DISCLOSURE OF THE INVENTION

[0020] Objects of the present invention is to provide a novel amino acid N-carboxyanhydride with an N-acyl substituent on a nitrogen atom thereof, which is considered to be an important intermediate extremely useful in many fields led by the fields of pharmaceuticals and agrochemicals but cannot be obtained by the conventional production techniques, and its production process, and a production process of a diamide compound, which owing to use of the N-carboxyanhydride, does not develop problems such as racemization, includes fewer steps and is economical.

[0021] The present inventors have proceeded with an extensive investigation to achieve the above-described objects. As a result, they have succeeded in obtaining a novel amino acid N-carboxyanhydride with an N-acyl substituent on a nitrogen atom thereof and based on use of the compound, have also found a novel amidation reaction which does not develop problems such as racemization, leading to the completion of the present invention.

[0022] Described specifically, an amino acid N-carboxy-anhydride with a substituent on a nitrogen atom thereof according to the present invention has a structure represented by the following formula (1):

[0023] wherein R¹ and R² each independently represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heterocyclic alkyl group.

[0024] Examples of the invention compound represented by the formula (1) can include the following compounds:

[0025] 1. Among compounds represented by the formula (1), those falling within neither the following category A nor the following category B:

[0026] A. Compounds of the formula (1) in which R²is a 2-oxopropyl group; and

[0027] B. Compounds of the following formulas (2) and (3):

[0028] 2. Compounds of the formula (1) in which R² is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, or a substituted or unsubstituted aralkyl group.

[0029] 3. Compounds of the formula (1) in which R² is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, or a substituted or unsubstituted aralkyl group, with a proviso that the compounds falling within the above category A or B are excluded.

[0030] 4. Compounds of the formula (1) in which R² is a substituted or unsubstituted aryl group.

[0031] 5. Compounds of the formula (1) in which R² is a substituted or unsubstituted aryl group, with a proviso that the compounds falling within the above category B are excluded.

[0032] 6. Compounds of the formula (1) in which R² is a substituted or unsubstituted heterocycle or a substituted or unsubstituted heterocyclic alkyl group.

[0033] 7. Compounds of the formula (1) in which R¹ is a side chain on an α-carbon atom of a protected or unprotected amino acid.

[0034] 8. Compounds having any one of the structures described above under items 1-6, in which R¹ is a side chain on an α-carbon atom of a protected or unprotected amino acid.

[0035] A process according to the present invention for the production of the compound represented by the formula (1), in a first aspect thereof, comprises reacting, in an inert diluent and in the presence of a condensing agent, an amino acid N-carboxyanhydride represented by the following formula (4):

[0036] wherein R¹ has the same meaning as defined in claim 1 with a compound represented by the following formula (5):

[0037] wherein R² has the same meaning as defined in claim 1.

[0038] The process according to the present invention for the production of the compound represented by the formula (1), in a second aspect thereof, comprises reacting, in an inert diluent and in the presence of an amine base, an amino acid N-carboxyanhydride represented by the following formula (4):

[0039] wherein R¹ has the same meaning as defined in claim 1 with a compound represented by the following formula (6):

[0040] wherein R² has the same meaning as defined in claim 1 and Y represents a halogen atom.

[0041] A process according to the present invention for the production of an amide derivative represented by the following formula (8):

[0042] wherein R¹ and R² have the same meanings as defined above, and R³ and R⁴ each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heterocyclic alkyl group, which comprises a step of reacting a compound represented by the formula (1), for example, any one of the compounds exemplified above under items 1-8 with an amine derivative represented by the following formula (7):

[0043] wherein R³ and R⁴ have the same meanings as defined above.

[0044] The process according to the present invention for the production of the compound represented by the formula (8), in another aspect thereof, comprises a step of reacting a compound represented by the formula (1), for example, any one of the compounds exemplified above under items 1-8 with an unprotected or protected amino acid.

BEST MODES FOR CARRYING OUT THE INVENTION

[0045] The compounds according to the present invention will next be described in further detail.

[0046] The term “substituted or unsubstituted alkyl group” represented by R¹, R², R³ and R⁴ in the formulas (1), (4), (5), (6), (7) and (8) means an alkyl group which may be substituted at one or more desired parts thereof. Examples of the alkyl group can include methyl, ethyl, methoxyethyl, phenoxymethyl, benzyloxymethyl, methylthiomethyl, phenylthiomethyl, fluorenylmethyl, fluoroethyl, n-propyl, chloropropyl, isopropyl, n-butyl, (substituted amino)-n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.

[0047] The term “substituted or unsubstituted cycloalkyl group” means a cycloalkyl group which may be substituted at one or more desired parts thereof. Examples of the cycloalkyl group can include cyclopropyl, cyclobutyl, cyclopentyl, ethoxycyclopentyl, cyclohexyl, tert-butoxycyclohexyl, benzyloxycyclohexyl, nitrocyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.

[0048] The term “substituted or unsubstituted aralkyl group” means an aralkyl group which may be substituted at one or more desired parts thereof. Examples of the aralkyl group can include benzyl, 2-phenylethyl, 3-phenylpropyl, cinnamyl, naphthylmethyl, 3-chlorobenzyl, 4-aminobenzyl, 2-nitrobenzyl, 4-methoxybenzyl, 3,4-dihydroxybenzyl, and 3,4-dimethoxybenzyl.

[0049] The term “substituted or unsubstituted aryl group” means an aryl group which may be substituted at one or more desired parts thereof. Examples of the aryl group can include phenyl, tolyl, bromophenyl, methoxyphenyl, ethylphenyl, propylphenyl, nitrophenyl, amidophenyl, fluorenyl, naphthyl, hydroxynaphthyl, anthracenyl, phenanthrenyl, and benzophenanthrenyl.

[0050] The term “substituted or unsubstituted heterocycle” means a heterocycle which may be substituted at one or more desired parts thereof. Examples of the heterocycle can include tetrahydropyranyl, tetrahydrofuranyl, alkyltetrahydrofuranyl, tetrahydrothienyl, methylsulfonyltetrahydrothienyl, pyridyl, pyrazyl, pyrimidyl, thienyl, hydroxypyridyl, imidazolyl, thiazolyl, pyrazolyl, pyrazolonyl, isoxazolyl, isothiazyl, pyrrolyl, furanyl, naphthylidinyl, quinolyl, sulfamoylquinolyl, and sydononyl.

[0051] The term “substituted or unsubstituted heterocyclic alkyl group” means a heterocyclic alkyl group which may be substituted at one or more desired parts thereof. Examples of the heterocyclic alkyl group can include 3-pyridylmethyl, 4-pyridylmethyl, 6-methoxy-3-pyridylmethyl, 3-quinolylmethyl, N-methyl-4-imidazolemethyl, 2-amino-4-thiazolemethyl, and morpholinomethyl.

[0052] The term “side chain on an α-carbon atom of a protected or unprotected amino acid” means a side chain on an α-carbon atom of an amino acid such as alanine or valine, leucine, isoleucine, tert-leucine, serine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine, hydroxylysine, arginine, cysteine, cystine, methionine, phenylalanine, tyrosine, tryptophan, histidine, homoserine or ornithine, for example. Representative examples of the side chain can include those represented by the following formulas (9) to (29):

[0053] The above-described side chains may be protected with protecting groups by methods, both of which are known commonly to those having ordinary skill in the art, as desired. For example, they may be protected using a commonly-employed, amino-protecting group, thiol-protecting group or carboxy-protecting group.

[0054] Illustrative inert diluents, which are usable in the first and second aspects of the process according to the present invention for the production of the compound represented by the formula (1), are chlorine-containing organic solvents such as methylene chloride, chloroform, carbon tetrachloride, dichloroethane and tetrachloroethane; esters such as methyl acetate, ethyl acetate and butyl acetate; ethers such as diethyl ether, diphenyl ether, dioxane and tetrahydrofuran; and hexane, liquid sulfur dioxide, carbon disulfide, benzene, toluene, xylene, nitromethane, nitrobenzene, acetonitrile, dimethylformamide, dimethylacetamide, and 1,3-dimethyl-2-imidazolidinone. They can be used either singly or in combination as needed.

[0055] Examples of the condensing agent can include thionyl chloride, thionyl bromide, N,N-dicyclohexylcarbodiimide, and 1,1-carbonyldiimidazole. They can be used either singly or in combination as needed.

[0056] Examples of the halogen atom represented by Y in the formula (6) can include a chlorine atom, bromine atom and iodine atom.

[0057] Illustrative of the amine base are trimethylamine, triethylamine, tributylamine, diisopropylethylamine, pyridine, lutidine, N,N-dimethylaniline, N,N-dimethyl-toluidine, 4-dimethylaminopyridine, N-methylmorpholine, diazabicycloundecene, and 1,8-bis(dimethylamino)-naphthalene.

[0058] Examples of the protected or unprotected amino acid usable as an amine in the production process of the compound of the formula (8) can include alanine, valine, leucine, isoleucine, tert-leucine, serine, threonine, aspartic acid, glutamic acid, asparagine, glutamine, lysine, hydroxylysine, arginine, cysteine, cystine, methionine, phenylalanine, tyrosine, tryptophan, histidine, homoserine, and ornithine. They can be used either singly or in combination as needed.

[0059] When the invention derivative represented by the formula (1) contains one or more asymmetric carbon atoms, the derivative may exist in the form of a specific stereoisomer or in the form of a mixture of stereoisomers including a racemic form.

[0060] Compounds encompassed by the formula (1) will be exemplified in Table 1 to Table 46, although they shall by no means restrict the compound according to the present invention. Incidentally, “Ph” in the tables means “a phenyl group” or “a phenylene group”. TABLE 1

Compound No. R2 Compound No. R2 1001 CH3 1045

1002 CH2CH3 1046

1003 (CH2)2CH3 1047

1004 CH(CH3)2 1048

1005 (CH2)3CH3 1049

1006 CH2CH(CH3)2 1050

1007 CH(CH3)CH2CH3 1051

1008 C(CH3)3 1052

1009 (CH2)4CH3 1053

1010 (CH2)5CH3 1054

1011 (CH2)6CH3 1055

1012 (CH2)7CH3 1056

1013 (CH2)8CH3 1057

1014 cyclopropyl 1058

1015 cyclobutyl 1059

1016 cyclohexyl 1060

1017 Ph 1061

1018 PhCH2 1062

1019 Ph(CH2)2 1020 Ph(CH2)3 1021 PhO(CH2)2 1022 PhCH2OCH2CH2 1023 PhCH2O(C═O)CH2CH2 1024 o-CH3Ph 1025 m-CH3Ph 1026 p-CH3Ph 1027 2,4-(CH3)2Ph 1028 3,5-(CH3)2Ph 1029 2,4,6-(CH3)3Ph 1030 p-CH3OPh 1031 p-CH3CH2OPh 1032 p-CH3(CH2)2OPh 1033 p-FPh 1034 p-ClPh 1035 p-BrPh 1036 p-IPh 1037 p-PhOPh 1038 p-PhCH2OPh 1039 p-NO2Ph 1040 p-CNPh 1041 p-CH3SO2Ph 1042

1043

1044

[0061] TABLE 2

Compound No. R2 Compound No. R2 2001 CH3 2045

2002 CH2CH3 2046

2003 (CH2)2CH3 2047

2004 CH(CH3)2 2048

2005 (CH2)3CH3 2049

2006 CH2CH(CH3)2 2050

2007 CH(CH3)CH2CH3 2051

2008 C(CH3)3 2052

2009 (CH2)4CH3 2053

2020 (CH2)5CH3 2054

2011 (CH2)6CH3 2055

2012 (CH2)7CH3 2056

2013 (CH2)8CH3 2057

2014 cyclopropyl 2058

2015 cyclobutyl 2059

2016 cyclohexyl 2060

2017 Ph 2061

2018 PhCH2 2062

2019 Ph(CH2)2 2020 Ph(CH2)3 2021 PhO(CH2)2 2022 PhCH2OCH2CH2 2023 PhCH2O(C═O)CH2CH2 2024 o-CH3Ph 2025 m-CH3Ph 2026 p-CH3Ph 2027 2,4-(CH3)2Ph 2028 3,5-(CH3)2Ph 2029 2,4,6-(CH3)3Ph 2030 p-CH3OPh 2031 p-CH3CH2OPh 2032 p-CH3(CH2)2OPh 2033 p-FPh 2034 p-ClPh 2035 p-BrPh 2036 p-IPh 2037 p-PhOPh 2038 p-PhCH2OPh 2039 p-NO2Ph 2040 p-CNPh 2041 p-CH3SO2Ph 2042

2043

2044

[0062] TABLE 3

Compound No. R2 Compound No. R2 3001 CH3 3045

3002 CH2CH3 3046

3003 (CH2)2CH3 3047

3004 CH(CH3)2 3048

3005 (CH2)3CH3 3049

3006 CH2CH(CH3)2 3050

3007 CH(CH3)CH2CH3 3051

3008 C(CH3)3 3052

3009 (CH2)4CH3 3053

3030 (CH2)5CH3 3054

3011 (CH2)6CH3 3055

3012 (CH2)7CH3 3056

3013 (CH2)8CH3 3057

3014 cyclopropyl 3058

3015 cyclobutyl 3059

3016 cyclohexyl 3060

3017 Ph 3061

3018 PhCH2 3062

3019 Ph(CH2)2 3020 Ph(CH2)3 3021 PhO(CH2)2 3022 PhCH2OCH2CH2 3023 PhCH2O(C═O)CH2CH2 3024 o-CH3Ph 3025 m-CH3Ph 3026 p-CH3Ph 3027 2,4-(CH3)2Ph 3028 3,5-(CH3)2Ph 3029 2,4,6-(CH3)3Ph 3030 p-CH3OPh 3031 p-CH3CH2OPh 3032 p-CH3(CH2)2OPh 3033 p-FPh 3034 p-ClPh 3035 p-BrPh 3036 p-IPh 3037 p-PhOPh 3038 p-PhCH2OPh 3039 p-NO2Ph 3040 p-CNPh 3041 p-CH3SO2Ph 3042

3043

3044

[0063] TABLE 4

Compound No. R2 Compound No. R2 4001 CH3 4045

4002 CH2CH3 4046

4003 (CH2)2CH3 4047

4004 CH(CH3)2 4048

4005 (CH2)3CH3 4049

4006 CH2CH(CH3)2 4050

4007 CH(CH3)CH2CH3 4051

4008 C(CH3)3 4052

4009 (CH2)4CH3 4053

4040 (CH2)5CH3 4054

4011 (CH2)6CH3 4055

4012 (CH2)7CH3 4056

4013 (CH2)8CH3 4057

4014 cyclopropyl 4058

4015 cyclobutyl 4059

4016 cyclohexyl 4060

4017 Ph 4061

4018 PhCH2 4062

4019 Ph(CH2)2 4020 Ph(CH2)3 4021 PhO(CH2)2 4022 PhCH2OCH2CH2 4023 PhCH2O(C═O)CH2CH2 4024 o-CH3Ph 4025 m-CH3Ph 4026 p-CH3Ph 4027 2,4-(CH3)2Ph 4028 3,5-(CH3)2Ph 4029 2,4,6-(CH3)3Ph 4030 p-CH3OPh 4031 p-CH3CH2OPh 4032 p-CH3(CH2)2OPh 4033 p-FPh 4034 p-ClPh 4035 p-BrPh 4036 p-IPh 4037 p-PhOPh 4038 p-PhCH2OPh 4039 p-NO2Ph 4040 p-CNPh 4041 p-CH3SO2Ph 4042

4043

4044

[0064] TABLE 5

Compound No. R2 Compound No. R2 5001 CH3 5045

5002 CH2CH3 5046

5003 (CH2)2CH3 5047

5004 CH(CH3)2 5048

5005 (CH2)3CH3 5049

5006 CH2CH(CH3)2 5050

5007 CH(CH3)CH2CH3 5051

5008 C(CH3)3 5052

5009 (CH2)4CH3 5053

5050 (CH2)5CH3 5054

5011 (CH2)6CH3 5055

5012 (CH2)7CH3 5056

5013 (CH2)8CH3 5057

5014 cyclopropyl 5058

5015 cyclobutyl 5059

5016 cyclohexyl 5060

5017 Ph 5061

5018 PhCH2 5062

5019 Ph(CH2)2 5020 Ph(CH2)3 5021 PhO(CH2)2 5022 PhCH2OCH2CH2 5023 PhCH2O(C═O)CH2CH2 5024 o-CH3Ph 5025 m-CH3Ph 5026 p-CH3Ph 5027 2,4-(CH3)2Ph 5028 3,5-(CH3)2Ph 5029 2,4,6-(CH3)3Ph 5030 p-CH3OPh 5031 p-CH3CH2OPh 5032 p-CH3(CH2)2OPh 5033 p-FPh 5034 p-ClPh 5035 p-BrPh 5036 p-IPh 5037 p-PhOPh 5038 p-PhCH2OPh 5039 p-NO2Ph 5040 p-CNPh 5041 p-CH3SO2Ph 5042

5043

5044

[0065] TABLE 6

Compound No. R2 Compound No. R2 6001 CH3 6045

6002 CH2CH3 6046

6003 (CH2)2CH3 6047

6004 CH(CH3)2 6048

6005 (CH2)3CH3 6049

6006 CH2CH(CH3)2 6050

6007 CH(CH3)CH2CH3 6051

6008 C(CH3)3 6052

6009 (CH2)4CH3 6053

6060 (CH2)5CH3 6054

6011 (CH2)6CH3 6055

6012 (CH2)7CH3 6056

6013 (CH2)8CH3 6057

6014 cyclopropyl 6058

6015 cyclobutyl 6059

6016 cyclohexyl 6060

6017 Ph 6061

6018 PhCH2 6062

6019 Ph(CH2)2 6020 Ph(CH2)3 6021 PhO(CH2)2 6022 PhCH2OCH2CH2 6023 PhCH2O(C═O)CH2CH2 6024 o-CH3Ph 6025 m-CH3Ph 6026 p-CH3Ph 6027 2,4-(CH3)2Ph 6028 3,5-(CH3)2Ph 6029 2,4,6-(CH3)3Ph 6030 p-CH3OPh 6031 p-CH3CH2OPh 6032 p-CH3(CH2)2OPh 6033 p-FPh 6034 p-ClPh 6035 p-BrPh 6036 p-IPh 6037 p-PhOPh 6038 p-PhCH2OPh 6039 p-NO2Ph 6040 p-CNPh 6041 p-CH3SO2Ph 6042

6043

6044

[0066] TABLE 7

Compound No. R2 Compound No. R2 7001 CH3 7045

7002 CH2CH3 7046

7003 (CH2)2CH3 7047

7004 CH(CH3)2 7048

7005 (CH2)3CH3 7049

7006 CH2CH(CH3)2 7050

7007 CH(CH3)CH2CH3 7051

7008 C(CH3)3 7052

7009 (CH2)4CH3 7053

7070 (CH2)5CH3 7054

7011 (CH2)6CH3 7055

7012 (CH2)7CH3 7056

7013 (CH2)8CH3 7057

7014 cyclopropyl 7058

7015 cyclobutyl 7059

7016 cyclohexyl 7060

7017 Ph 7061

7018 PhCH2 7062

7019 Ph(CH2)2 7020 Ph(CH2)3 7021 PhO(CH2)2 7022 PhCH2OCH2CH2 7023 PhCH2O(C═O)CH2CH2 7024 o-CH3Ph 7025 m-CH3Ph 7026 p-CH3Ph 7027 2,4-(CH3)2Ph 7028 3,5-(CH3)2Ph 7029 2,4,6-(CH3)3Ph 7030 p-CH3OPh 7031 p-CH3CH2OPh 7032 p-CH3(CH2)2OPh 7033 p-FPh 7034 p-ClPh 7035 p-BrPh 7036 p-IPh 7037 p-PhOPh 7038 p-PhCH2OPh 7039 p-NO2Ph 7040 p-CNPh 7041 p-CH3SO2Ph 7042

7043

7044

[0067] TABLE 8

Compound No. R2 Compound No. R2 8001 CH3 8045

8002 CH2CH3 8046

8003 (CH2)2CH3 8047

8004 CH(CH3)2 8048

8005 (CH2)3CH3 8049

8006 CH2CH(CH3)2 8050

8007 CH(CH3)CH2CH3 8051

8008 C(CH3)3 8052

8009 (CH2)4CH3 8053

8080 (CH2)5CH3 8054

8011 (CH2)6CH3 8055

8012 (CH2)7CH3 8056

8013 (CH2)8CH3 8057

8014 cyclopropyl 8058

8015 cyclobutyl 8059

8016 cyclohexyl 8060

8017 Ph 8061

8018 PhCH2 8062

8019 Ph(CH2)2 8020 Ph(CH2)3 8021 PhO(CH2)2 8022 PhCH2OCH2CH2 8023 PhCH2O(C═O)CH2CH2 8024 o-CH3Ph 8025 m-CH3Ph 8026 p-CH3Ph 8027 2,4-(CH3)2Ph 8028 3,5-(CH3)2Ph 8029 2,4,6-(CH3)3Ph 8030 p-CH3OPh 8031 p-CH3CH2OPh 8032 p-CH3(CH2)2OPh 8033 p-FPh 8034 p-ClPh 8035 p-BrPh 8036 p-IPh 8037 p-PhOPh 8038 p-PhCH2OPh 8039 p-NO2Ph 8040 p-CNPh 8041 p-CH3SO2Ph 8042

8043

8044

[0068] TABLE 9

Compound No. R2 Compound No. R2 9001 CH3 9045

9002 CH2CH3 9046

9003 (CH2)2CH3 9047

9004 CH(CH3)2 9048

9005 (CH2)3CH3 9049

9006 CH2CH(CH3)2 9050

9007 CH(CH3)CH2CH3 9051

9008 C(CH3)3 9052

9009 (CH2)4CH3 9053

9090 (CH2)5CH3 9054

9011 (CH2)6CH3 9055

9012 (CH2)7CH3 9056

9013 (CH2)8CH3 9057

9014 cyclopropyl 9058

9015 cyclobutyl 9059

9016 cyclohexyl 9060

9017 Ph 9061

9018 PhCH2 9062

9019 Ph(CH2)2 9020 Ph(CH2)3 9021 PhO(CH2)2 9022 PhCH2OCH2CH2 9023 PhCH2O(C═O)CH2CH2 9024 o-CH3Ph 9025 m-CH3Ph 9026 p-CH3Ph 9027 2,4-(CH3)2Ph 9028 3,5-(CH3)2Ph 9029 2,4,6-(CH3)3Ph 9030 p-CH3OPh 9031 p-CH3CH2OPh 9032 p-CH3(CH2)2OPh 9033 p-FPh 9034 p-ClPh 9035 p-BrPh 9036 p-IPh 9037 p-PhOPh 9038 p-PhCH2OPh 9039 p-NO2Ph 9040 p-CNPh 9041 p-CH3SO2Ph 9042

9043

9044

[0069] TABLE 10

Compound No. R2 Compound No. R2 10001 CH3 10045

10002 CH2CH3 10046

10003 (CH2)2CH3 10047

10004 CH(CH3)2 10048

10005 (CH2)3CH3 10049

10006 CH2CH(CH3)2 10050

10007 CH(CH3)CH2CH3 10051

10008 C(CH3)3 10052

10009 (CH2)4CH3 10053

10010 (CH2)5CH3 10054

10011 (CH2)6CH3 10055

10012 (CH2)7CH3 10056

10013 (CH2)8CH3 10057

10014 cyclopropyl 10058

10015 cyclobutyl 10059

10016 cyclohexyl 10060

10017 Ph 10061

10018 PhCH2 10062

10019 Ph(CH2)2 10020 Ph(CH2)3 10021 PhO(CH2)2 10022 PhCH2OCH2CH2 10023 PhCH2O(C═O)CH2CH2 10024 o-CH3Ph 10025 m-CH3Ph 10026 p-CH3Ph 10027 2,4-(CH3)2Ph 10028 3,5-(CH3)2Ph 10029 2,4,6-(CH3)3Ph 10030 p-CH3OPh 10031 p-CH3CH2OPh 10032 p-CH3(CH2)2OPh 10033 p-FPh 10034 p-ClPh 10035 p-BrPh 10036 p-IPh 10037 p-PhOPh 10038 p-PhCH2OPh 10039 p-NO2Ph 10040 p-CNPh 10041 p-CH3SO2Ph 10042

10043

10044

[0070] TABLE 11

Compound No. R2 11001 CH3 11002 CH2CH3 11003 (CH2)2CH3 11004 CH(CH3)2 11005 (CH2)3CH3 11006 CH2CH(CH3)2 11007 CH(CH3)CH2CH3 11008 C(CH3)3 11009 (CH2)4CH3 11010 (CH2)5CH3 11011 (CH2)6CH3 11012 (CH2)7CH3 11013 (CH2)8CH3 11014 cyclopropyl 11015 cyclobutyl 11016 cyclohexyl 11017 Ph 11018 PhCH2 11019 Ph(CH2)2 11020 Ph(CH2)3 11021 PhO(CH2)2 11022 PhCH2OCH2CH2 11023 PhCH2O(C═O)CH2CH2 11024 o-CH3Ph 11025 m-CH3Ph 11026 p-CH3Ph 11027 2,4-(CH3)2Ph 11028 3,5-(CH3)2Ph 11029 2,4,6-(CH3)3Ph 11030 p-CH3OPh 11031 p-CH3CH2OPh 11032 p-CH3(CH2)2OPh 11033 p-FPh 11034 p-ClPh 11035 p-BrPh 11036 p-IPh 11037 p-PhOPh 11038 p-PhCH2OPh 11039 p-NO2Ph 11040 p-CNPh 11041 p-CH3SO2Ph 11042

11043

11044

11045

11046

11047

11048

11049

11050

11051

11052

11053

11054

11055

11056

11057

11058

11059

11060

11061

11062

[0071] TABLE 12

Compound No. R2 12001 CH3 12002 CH2CH3 12003 (CH2)2CH3 12004 CH(CH3)2 12005 (CH2)3CH3 12006 CH2CH(CH3)2 12007 CH(CH3)CH2CH3 12008 C(CH3)3 12009 (CH2)4CH3 12010 (CH2)5CH3 12011 (CH2)6CH3 12012 (CH2)7CH3 12013 (CH2)8CH3 12014 cyclopropyl 12015 cyclobutyl 12016 cyclohexyl 12017 Ph 12018 PhCH2 12019 Ph(CH2)2 12020 Ph(CH2)3 12021 PhO(CH2)2 12022 PhCH2OCH2CH2 12023 PhCH2O(C═O)CH2CH2 12024 o-CH3Ph 12025 m-CH3Ph 12026 p-CH3Ph 12027 2,4-(CH3)2Ph 12028 3,5-(CH3)2Ph 12029 2,4,6-(CH3)3Ph 12030 p-CH3OPh 12031 p-CH3CH2OPh 12032 p-CH3(CH2)2OPh 12033 p-FPh 12034 p-ClPh 12035 p-BrPh 12036 p-IPh 12037 p-PhOPh 12038 p-PhCH2OPh 12039 p-NO2Ph 12040 p-CNPh 12041 p-CH3SO2Ph 12042

12043

12044

12045

12046

12047

12048

12049

12050

12051

12052

12053

12054

12055

12056

12057

12058

12059

12060

12061

12062

[0072] TABLE 13

Compound No. R2 13001 CH3 13002 CH2CH3 13003 (CH2)2CH3 13004 CH(CH3)2 13005 (CH2)3CH3 13006 CH2CH(CH3)2 13007 CH(CH3)CH2CH3 13008 C(CH3)3 13009 (CH2)4CH3 13010 (CH2)5CH3 13011 (CH2)6CH3 13012 (CH2)7CH3 13013 (CH2)8CH3 13014 cyclopropyl 13015 cyclobutyl 13016 cyclohexyl 13017 Ph 13018 PhCH2 13019 Ph(CH2)2 13020 Ph(CH2)3 13021 PhO(CH2)2 13022 PhCH2OCH2CH2 13023 PhCH2O(C═O)CH2CH2 13024 o-CH3Ph 13025 m-CH3Ph 13026 p-CH3Ph 13027 2,4-(CH3)2Ph 13028 3,5-(CH3)2Ph 13029 2,4,6-(CH3)3Ph 13030 p-CH3OPh 13031 p-CH3CH2OPh 13032 p-CH3(CH2)2OPh 13033 p-FPh 13034 p-ClPh 13035 p-BrPh 13036 p-IPh 13037 p-PhOPh 13038 p-PhCH2OPh 13039 p-NO2Ph 13040 p-CNPh 13041 p-CH3SO2Ph 13042

13043

13044

13045

13046

13047

13048

13049

13050

13051

13052

13053

13054

13055

13056

13057

13058

13059

13060

13061

13062

[0073] TABLE 14

Compound No. R2 14001 CH3 14002 CH2CH3 14003 (CH2)2CH3 14004 CH(CH3)2 14005 (CH2)3CH3 14006 CH2CH(CH3)2 14007 CH(CH3)CH2CH3 14008 C(CH3)3 14009 (CH2)4CH3 14010 (CH2)5CH3 14011 (CH2)6CH3 14012 (CH2)7CH3 14013 (CH2)8CH3 14014 cyclopropyl 14015 cyclobutyl 14016 cyclohexyl 14017 Ph 14018 PhCH2 14019 Ph(CH2)2 14020 Ph(CH2)3 14021 PhO(CH2)2 14022 PhCH2OCH2CH2 14023 PhCH2O(C═O)CH2CH2 14024 o-CH3Ph 14025 m-CH3Ph 14026 p-CH3Ph 14027 2,4-(CH3)2Ph 14028 3,5-(CH3)2Ph 14029 2,4,6-(CH3)3Ph 14030 p-CH3OPh 14031 p-CH3CH2OPh 14032 p-CH3(CH2)2OPh 14033 p-FPh 14034 p-ClPh 14035 p-BrPh 14036 p-IPh 14037 p-PhOPh 14038 p-PhCH2OPh 14039 p-NO2Ph 14040 p-CNPh 14041 p-CH3SO2Ph 14042

14043

14044

14045

14046

14047

14048

14049

14050

14051

14052

14053

14054

14055

14056

14057

14058

14059

14060

14061

14062

[0074] TABLE 15

Compound No. R2 15001 CH3 15002 CH2CH3 15003 (CH2)2CH3 15004 CH(CH3)2 15005 (CH2)3CH3 15006 CH2CH(CH3)2 15007 CH(CH3)CH2CH3 15008 C(CH3)3 15009 (CH2)4CH3 15010 (CH2)5CH3 15011 (CH2)6CH3 15012 (CH2)7CH3 15013 (CH2)8CH3 15014 cyclopropyl 15015 cyclobutyl 15016 cyclohexyl 15017 Ph 15018 PhCH2 15019 Ph(CH2)2 15020 Ph(CH2)3 15021 PhO(CH2)2 15022 PhCH2OCH2CH2 15023 PhCH2O(C═O)CH2CH2 15024 o-CH3Ph 15025 m-CH3Ph 15026 p-CH3Ph 15027 2,4-(CH3)2Ph 15028 3,5-(CH3)2Ph 15029 2,4,6-(CH3)3Ph 15030 p-CH3OPh 15031 p-CH3CH2OPh 15032 p-CH3(CH2)2OPh 15033 p-FPh 15034 p-ClPh 15035 p-BrPh 15036 p-IPh 15037 p-PhOPh 15038 p-PhCH2OPh 15039 p-NO2Ph 15040 p-CNPh 15041 p-CH3SO2Ph 15042

15043

15044

15045

15046

15047

15048

15049

15050

15051

15052

15053

15054

15055

15056

15057

15058

15059

15060

15061

15062

[0075] TABLE 16

Compound No. R2 16001 CH3 16002 CH2CH3 16003 (CH2)2CH3 16004 CH(CH3)2 16005 (CH2)3CH3 16006 CH2CH(CH3)2 16007 CH(CH3)CH2CH3 16008 C(CH3)3 16009 (CH2)4CH3 16010 (CH2)5CH3 16011 (CH2)6CH3 16012 (CH2)7CH3 16013 (CH2)8CH3 16014 cyclopropyl 16015 cyclobutyl 16016 cyclohexyl 16017 Ph 16018 PhCH2 16019 Ph(CH2)2 16020 Ph(CH2)3 16021 PhO(CH2)2 16022 PhCH2OCH2CH2 16023 PhCH2O(C═O)CH2CH2 16024 o-CH3Ph 16025 m-CH3Ph 16026 p-CH3Ph 16027 2,4-(CH3)2Ph 16028 3,5-(CH3)2Ph 16029 2,4,6-(CH3)3Ph 16030 p-CH3OPh 16031 p-CH3CH2OPh 16032 p-CH3(CH2)2OPh 16033 p-FPh 16034 p-ClPh 16035 p-BrPh 16036 p-IPh 16037 p-PhOPh 16038 p-PhCH2OPh 16039 p-NO2Ph 16040 p-CNPh 16041 p-CH3SO2Ph 16042

16043

16044

16045

16046

16047

16048

16049

16050

16051

16052

16053

16054

16055

16056

16057

16058

16059

16060

16061

16062

[0076] TABLE 17

Compound No. R2 17001 CH3 17002 CH2CH3 17003 (CH2)2CH3 17004 CH(CH3)2 17005 (CH2)3CH3 17006 CH2CH(CH3)2 17007 CH(CH3)CH2CH3 17008 C(CH3)3 17009 (CH2)4CH3 17010 (CH2)5CH3 17011 (CH2)6CH3 17012 (CH2)7CH3 17013 (CH2)8CH3 17014 cyclopropyl 17015 cyclobutyl 17016 cyclohexyl 17017 Ph 17018 PhCH2 17019 Ph(CH2)2 17020 Ph(CH2)3 17021 PhO(CH2)2 17022 PhCH2OCH2CH2 17023 PhCH2O(C═O)CH2CH2 17024 o-CH3Ph 17025 m-CH3Ph 17026 p-CH3Ph 17027 2,4-(CH3)2Ph 17028 3,5-(CH3)2Ph 17029 2,4,6-(CH3)3Ph 17030 p-CH3OPh 17031 p-CH3CH2OPh 17032 p-CH3(CH2)2OPh 17033 p-FPh 17034 p-ClPh 17035 p-BrPh 17036 p-IPh 17037 p-PhOPh 17038 p-PhCH2OPh 17039 p-NO2Ph 17040 p-CNPh 17041 p-CH3SO2Ph 17042

17043

17044

17045

17046

17047

17048

17049

17050

17051

17052

17053

17054

17055

17056

17057

17058

17059

17060

17061

17062

[0077] TABLE 18

Compound No. R2 18001 CH3 18002 CH2CH3 18003 (CH2)2CH3 18004 CH(CH3)2 18005 (CH2)3CH3 18006 CH2CH(CH3)2 18007 CH(CH3)CH2CH3 18008 C(CH3)3 18009 (CH2)4CH3 18010 (CH2)5CH3 18011 (CH2)6CH3 18012 (CH2)7CH3 18013 (CH2)8CH3 18014 cyclopropyl 18015 cyclobutyl 18016 cyclohexyl 18017 Ph 18018 PhCH2 18019 Ph(CH2)2 18020 Ph(CH2)3 18021 PhO(CH2)2 18022 PhCH2OCH2CH2 18023 PhCH2O(C═O)CH2CH2 18024 o-CH3Ph 18025 m-CH3Ph 18026 p-CH3Ph 18027 2,4-(CH3)2Ph 18028 3,5-(CH3)2Ph 18029 2,4,6-(CH3)3Ph 18030 p-CH3OPh 18031 p-CH3CH2OPh 18032 p-CH3(CH2)2OPh 18033 p-FPh 18034 p-ClPh 18035 p-BrPh 18036 p-IPh 18037 p-PhOPh 18038 p-PhCH2OPh 18039 p-NO2Ph 18040 p-CNPh 18041 p-CH3SO2Ph 18042

18043

18044

18045

18046

18047

18048

18049

18050

18051

18052

18053

18054

18055

18056

18057

18058

18059

18060

18061

18062

[0078] TABLE 19

Compound No. R2 19001 CH3 19002 CH2CH3 19003 (CH2)2CH3 19004 CH(CH3)2 19005 (CH2)3CH3 19006 CH2CH(CH3)2 19007 CH(CH3)CH2CH3 19008 C(CH3)3 19009 (CH2)4CH3 19010 (CH2)5CH3 19011 (CH2)6CH3 19012 (CH2)7CH3 19013 (CH2)8CH3 19014 cyclopropyl 19015 cyclobutyl 19016 cyclohexyl 19017 Ph 19018 PhCH2 19019 Ph(CH2)2 19020 Ph(CH2)3 19021 PhO(CH2)2 19022 PhCH2OCH2CH2 19023 PhCH2O(C═O)CH2CH2 19024 o-CH3Ph 19025 m-CH3Ph 19026 p-CH3Ph 19027 2,4-(CH3)2Ph 19028 3,5-(CH3)2Ph 19029 2,4,6-(CH3)3Ph 19030 p-CH3OPh 19031 p-CH3CH2OPh 19032 p-CH3(CH2)2OPh 19033 p-FPh 19034 p-ClPh 19035 p-BrPh 19036 p-IPh 19037 p-PhOPh 19038 p-PhCH2OPh 19039 p-NO2Ph 19040 p-CNPh 19041 p-CH3SO2Ph 19042

19043

19044

19045

19046

19047

19048

19049

19050

19051

19052

19053

19054

19055

19056

19057

19058

19059

19060

19061

19062

[0079] TABLE 20

Compound No. R2 20001 CH3 20002 CH2CH3 20003 (CH2)2CH3 20004 CH(CH3)2 20005 (CH2)3CH3 20006 CH2CH(CH3)2 20007 CH(CH3)CH2CH3 20008 C(CH3)3 20009 (CH2)4CH3 20010 (CH2)5CH3 20011 (CH2)6CH3 20012 (CH2)7CH3 20013 (CH2)8CH3 20014 cyclopropyl 20015 cyclobutyl 20016 cyclohexyl 20017 Ph 20018 PhCH2 20019 Ph(CH2)2 20020 Ph(CH2)3 20021 PhO(CH2)2 20022 PhCH2OCH2CH2 20023 PhCH2O(C═O)CH2CH2 20024 o-CH3Ph 20025 m-CH3Ph 20026 p-CH3Ph 20027 2,4-(CH3)2Ph 20028 3,5-(CH3)2Ph 20029 2,4,6-(CH3)3Ph 20030 p-CH3OPh 20031 p-CH3CH2OPh 20032 p-CH3(CH2)2OPh 20033 p-FPh 20034 p-ClPh 20035 p-BrPh 20036 p-IPh 20037 p-PhOPh 20038 p-PhCH2OPh 20039 p-NO2Ph 20040 p-CNPh 20041 p-CH3SO2Ph 20042

20043

20044

20045

20046

20047

20048

20049

20050

20051

20052

20053

20054

20055

20056

20057

20058

20059

20060

20061

20062

[0080] TABLE 21

Compound No. R2 21001 CH3 21002 CH2CH3 21003 (CH2)2CH3 21004 CH(CH3)2 21005 (CH2)3CH3 21006 CH2CH(CH3)2 21007 CH(CH3)CH2CH3 21008 C(CH3)3 21009 (CH2)4CH3 21010 (CH2)5CH3 21011 (CH2)6CH3 21012 (CH2)7CH3 21013 (CH2)8CH3 21014 cyclopropyl 21015 cyclobutyl 21016 cyclohexyl 21017 Ph 21018 PhCH2 21019 Ph(CH2)2 21020 Ph(CH2)3 21021 PhO(CH2)2 21022 PhCH2OCH2CH2 21023 PhCH2O(C═O)CH2CH2 21024 o-CH3Ph 21025 m-CH3Ph 21026 p-CH3Ph 21027 2,4-(CH3)2Ph 21028 3,5-(CH3)2Ph 21029 2,4,6-(CH3)3Ph 21030 p-CH3OPh 21031 p-CH3CH2OPh 21032 p-CH3(CH2)2OPh 21033 p-FPh 21034 p-ClPh 21035 p-BrPh 21036 p-IPh 21037 p-PhOPh 21038 p-PhCH2OPh 21039 p-NO2Ph 21040 p-CNPh 21041 p-CH3SO2Ph 21042

21043

21044

21045

21046

21047

21048

21049

21050

21051

21052

21053

21054

21055

21056

21057

21058

21059

21060

21061

21062

[0081] TABLE 22

Compound No. R2 22001 CH3 22002 CH2CH3 22003 (CH2)2CH3 22004 CH(CH3)2 22005 (CH2)3CH3 22006 CH2CH(CH3)2 22007 CH(CH3)CH2CH3 22008 C(CH3)3 22009 (CH2)4CH3 22010 (CH2)5CH3 22011 (CH2)6CH3 22012 (CH2)7CH3 22013 (CH2)8CH3 22014 cyclopropyl 22015 cyclobutyl 22016 cyclohexyl 22017 Ph 22018 PhCH2 22019 Ph(CH2)2 22020 Ph(CH2)3 22021 PhO(CH2)2 22022 PhCH2OCH2CH2 22023 PhCH2O(C═O)CH2CH2 22024 o-CH3Ph 22025 m-CH3Ph 22026 p-CH3Ph 22027 2,4-(CH3)2Ph 22028 3,5-(CH3)2Ph 22029 2,4,6-(CH3)3Ph 22030 p-CH3OPh 22031 p-CH3CH2OPh 22032 p-CH3(CH2)2OPh 22033 p-FPh 22034 p-ClPh 22035 p-BrPh 22036 p-IPh 22037 p-PhOPh 22038 p-PhCH2OPh 22039 p-NO2Ph 22040 p-CNPh 22041 p-CH3SO2Ph 22042

22043

22044

22045

22046

22047

22048

22049

22050

22051

22052

22053

22054

22055

22056

22057

22058

22059

22060

22061

22062

[0082] TABLE 23

Compound No. R2 23001 CH3 23002 CH2CH3 23003 (CH2)2CH3 23004 CH(CH3)2 23005 (CH2)3CH3 23006 CH2CH(CH3)2 23007 CH(CH3)CH2CH3 23008 C(CH3)3 23009 (CH2)4CH3 23010 (CH2)5CH3 23011 (CH2)6CH3 23012 (CH2)7CH3 23013 (CH2)8CH3 23014 cyclopropyl 23015 cyclobutyl 23016 cyclohexyl 23017 Ph 23018 PhCH2 23019 Ph(CH2)2 23020 Ph(CH2)3 23021 PhO(CH2)2 23022 PhCH2OCH2CH2 23023 PhCH2O(C═O)CH2CH2 23024 o-CH3Ph 23025 m-CH3Ph 23026 p-CH3Ph 23027 2,4-(CH3)2Ph 23028 3,5-(CH3)2Ph 23029 2,4,6-(CH3)3Ph 23030 p-CH3OPh 23031 p-CH3CH2OPh 23032 p-CH3(CH2)2OPh 23033 p-FPh 23034 p-ClPh 23035 p-BrPh 23036 p-IPh 23037 p-PhOPh 23038 p-PhCH2OPh 23039 p-NO2Ph 23040 p-CNPh 23041 p-CH3SO2Ph 23042

23043

23044

23045

23046

23047

23048

23049

23050

23051

23052

23053

23054

23055

23056

23057

23058

23059

23060

23061

23062

[0083] TABLE 24

Compound No. R2 24001 CH3 24002 CH2CH3 24003 (CH2)2CH3 24004 CH(CH3)2 24005 (CH2)3CH3 24006 CH2CH(CH3)2 24007 CH(CH3)CH2CH3 24008 C(CH3)3 24009 (CH2)4CH3 24010 (CH2)5CH3 24011 (CH2)6CH3 24012 (CH2)7CH3 24013 (CH2)8CH3 24014 cyclopropyl 24015 cyclobutyl 24016 cyclohexyl 24017 Ph 24018 PhCH2 24019 Ph(CH2)2 24020 Ph(CH2)3 24021 PhO(CH2)2 24022 PhCH2OCH2CH2 24023 PhCH2O(C═O)CH2CH2 24024 o-CH3Ph 24025 m-CH3Ph 24026 p-CH3Ph 24027 2,4-(CH3)2Ph 24028 3,5-(CH3)2Ph 24029 2,4,6-(CH3)3Ph 24030 p-CH3OPh 24031 p-CH3CH2OPh 24032 p-CH3(CH2)2OPh 24033 p-FPh 24034 p-ClPh 24035 p-BrPh 24036 p-IPh 24037 p-PhOPh 24038 p-PhCH2OPh 24039 p-NO2Ph 24040 p-CNPh 24041 p-CH3SO2Ph 24042

24043

24044

24045

24046

24047

24048

24049

24050

24051

24052

24053

24054

24055

24056

24057

24058

24059

24060

24061

24062

[0084] TABLE 25

Compound No. R2 25001 CH3 25002 CH2CH3 25003 (CH2)2CH3 25004 CH(CH3)2 25005 (CH2)3CH3 25006 CH2CH(CH3)2 25007 CH(CH3)CH2CH3 25008 C(CH3)3 25009 (CH2)4CH3 25010 (CH2)5CH3 25011 (CH2)6CH3 25012 (CH2)7CH3 25013 (CH2)8CH3 25014 cyclopropyl 25015 cyclobutyl 25016 cyclohexyl 25017 Ph 25018 PhCH2 25019 Ph(CH2)2 25020 Ph(CH2)3 25021 PhO(CH2)2 25022 PhCH2OCH2CH2 25023 PhCH2O(C═O)CH2CH2 25024 o-CH3Ph 25025 m-CH3Ph 25026 p-CH3Ph 25027 2,4-(CH3)2Ph 25028 3,5-(CH3)2Ph 25029 2,4,6-(CH3)3Ph 25030 p-CH3OPh 25031 p-CH3CH2OPh 25032 p-CH3(CH2)2OPh 25033 p-FPh 25034 p-ClPh 25035 p-BrPh 25036 p-IPh 25037 p-PhOPh 25038 p-PhCH2OPh 25039 p-NO2Ph 25040 p-CNPh 25041 p-CH3SO2Ph 25042

25043

25044

25045

25046

25047

25048

25049

25050

25051

25052

25053

25054

25055

25056

25057

25058

25059

25060

25061

25062

[0085] TABLE 26

Compound No. R2 26001 CH3 26002 CH2CH3 26003 (CH2)2CH3 26004 CH(CH3)2 26005 (CH2)3CH3 26006 CH2CH(CH3)2 26007 CH(CH3)CH2CH3 26008 C(CH3)3 26009 (CH2)4CH3 26010 (CH2)5CH3 26011 (CH2)6CH3 26012 (CH2)7CH3 26013 (CH2)8CH3 26014 cyclopropyl 26015 cyclobutyl 26016 cyclohexyl 26017 Ph 26018 PhCH2 26019 Ph(CH2)2 26020 Ph(CH2)3 26021 PhO(CH2)2 26022 PhCH2OCH2CH2 26023 PhCH2O(C═O)CH2CH2 26024 o-CH3Ph 26025 m-CH3Ph 26026 p-CH3Ph 26027 2,4-(CH3)2Ph 26028 3,5-(CH3)2Ph 26029 2,4,6-(CH3)3Ph 26030 p-CH3OPh 26031 p-CH3CH2OPh 26032 p-CH3(CH2)2OPh 26033 p-FPh 26034 p-ClPh 26035 p-BrPh 26036 p-IPh 26037 p-PhOPh 26038 p-PhCH2OPh 26039 p-NO2Ph 26040 p-CNPh 26041 p-CH3SO2Ph 26042

26043

26044

26045

26046

26047

26048

26049

26050

26051

26052

26053

26054

26055

26056

26057

26058

26059

26060

26061

26062

[0086] TABLE 27

Compound No. R2 27001 CH3 27002 CH2CH3 27003 (CH2)2CH3 27004 CH(CH3)2 27005 (CH2)3CH3 27006 CH2CH(CH3)2 27007 CH(CH3)CH2CH3 27008 C(CH3)3 27009 (CH2)4CH3 27010 (CH2)5CH3 27011 (CH2)6CH3 27012 (CH2)7CH3 27013 (CH2)8CH3 27014 cyclopropyl 27015 cyclobutyl 27016 cyclohexyl 27017 Ph 27018 PhCH2 27019 Ph(CH2)2 27020 Ph(CH2)3 27021 PhO(CH2)2 27022 PhCH2OCH2CH2 27023 PhCH2O(C═O)CH2CH2 27024 o-CH3Ph 27025 m-CH3Ph 27026 p-CH3Ph 27027 2,4-(CH3)2Ph 27028 3,5-(CH3)2Ph 27029 2,4,6-(CH3)3Ph 27030 p-CH3OPh 27031 p-CH3CH2OPh 27032 p-CH3(CH2)2OPh 27033 p-FPh 27034 p-ClPh 27035 p-BrPh 27036 p-IPh 27037 p-PhOPh 27038 p-PhCH2OPh 27039 p-NO2Ph 27040 p-CNPh 27041 p-CH3SO2Ph 27042

27043

27044

27045

27046

27047

27048

27049

27050

27051

27052

27053

27054

27055

27056

27057

27058

27059

27060

27061

27062

[0087] TABLE 28

Compound No. R2 28001 CH3 28002 CH2CH3 28003 (CH2)2CH3 28004 CH(CH3)2 28005 (CH2)3CH3 28006 CH2CH(CH3)2 28007 CH(CH3)CH2CH3 28008 C(CH3)3 28009 (CH2)4CH3 28010 (CH2)5CH3 28011 (CH2)6CH3 28012 (CH2)7CH3 28013 (CH2)8CH3 28014 cyclopropyl 28015 cyclobutyl 28016 cyclohexyl 28017 Ph 28018 PhCH2 28019 Ph(CH2)2 28020 Ph(CH2)3 28021 PhO(CH2)2 28022 PhCH2OCH2CH2 28023 PhCH2O(C═O)CH2CH2 28024 o-CH3Ph 28025 m-CH3Ph 28026 p-CH3Ph 28027 2,4-(CH3)2Ph 28028 3,5-(CH3)2Ph 28029 2,4,6-(CH3)3Ph 28030 p-CH3OPh 28031 p-CH3CH2OPh 28032 p-CH3(CH2)2OPh 28033 p-FPh 28034 p-ClPh 28035 p-BrPh 28036 p-IPh 28037 p-PhOPh 28038 p-PhCH2OPh 28039 p-NO2Ph 28040 p-CNPh 28041 p-CH3SO2Ph 28042

28043

28044

28045

28046

28047

28048

28049

28050

28051

28052

28053

28054

28055

28056

28057

28058

28059

28060

28061

28062

[0088] TABLE 29

Compound No. R2 29001 CH3 29002 CH2CH3 29003 (CH2)2CH3 29004 CH(CH3)2 29005 (CH2)3CH3 29006 CH2CH(CH3)2 29007 CH(CH3)CH2CH3 29008 C(CH3)3 29009 (CH2)4CH3 29010 (CH2)5CH3 29011 (CH2)6CH3 29012 (CH2)7CH3 29013 (CH2)8CH3 29014 cyclopropyl 29015 cyclobutyl 29016 cyclohexyl 29017 Ph 29018 PhCH2 29019 Ph(CH2)2 29020 Ph(CH2)3 29021 PhO(CH2)2 29022 PhCH2OCH2CH2 29023 PhCH2O(C═O)CH2CH2 29024 o-CH3Ph 29025 m-CH3Ph 29026 p-CH3Ph 29027 2,4-(CH3)2Ph 29028 3,5-(CH3)2Ph 29029 2,4,6-(CH3)3Ph 29030 p-CH3OPh 29031 p-CH3CH2OPh 29032 p-CH3(CH2)2OPh 29033 p-FPh 29034 p-ClPh 29035 p-BrPh 29036 p-IPh 29037 p-PhOPh 29038 p-PhCH2OPh 29039 p-NO2Ph 29040 p-CNPh 29041 p-CH3SO2Ph 29042

29043

29044

29045

29046

29047

29048

29049

29050

29051

29052

29053

29054

29055

29056

29057

29058

29059

29060

29061

29062

[0089] TABLE 30

Compound No. R2 30001 CH3 30002 CH2CH3 30003 (CH2)2CH3 30004 CH(CH3)2 30005 (CH2)3CH3 30006 CH2CH(CH3)2 30007 CH(CH3)CH2CH3 30008 C(CH3)3 30009 (CH2)4CH3 30010 (CH2)5CH3 30011 (CH2)6CH3 30012 (CH2)7CH3 30013 (CH2)8CH3 30014 cyclopropyl 30015 cyclobutyl 30016 cyclohexyl 30017 Ph 30018 PhCH2 30019 Ph(CH2)2 30020 Ph(CH2)3 30021 PhO(CH2)2 30022 PhCH2OCH2CH2 30023 PhCH2O(C═O)CH2CH2 30024 o-CH3Ph 30025 m-CH3Ph 30026 p-CH3Ph 30027 2,4-(CH3)2Ph 30028 3,5-(CH3)2Ph 30029 2,4,6-(CH3)3Ph 30030 p-CH3OPh 30031 p-CH3CH2OPh 30032 p-CH3(CH2)2OPh 30033 p-FPh 30034 p-ClPh 30035 p-BrPh 30036 p-IPh 30037 p-PhOPh 30038 p-PhCH2OPh 30039 p-NO2Ph 30040 p-CNPh 30041 p-CH3SO2Ph 30042

30043

30044

30045

30046

30047

30048

30049

30050

30051

30052

30053

30054

30055

30056

30057

30058

30059

30060

30061

30062

[0090] TABLE 31

Compound No. R2 31001 CH3 31002 CH2CH3 31003 (CH2)2CH3 31004 CH(CH3)2 31005 (CH2)3CH3 31006 CH2CH(CH3)2 31007 CH(CH3)CH2CH3 31008 C(CH3)3 31009 (CH2)4CH3 31010 (CH2)5CH3 31011 (CH2)6CH3 31012 (CH2)7CH3 31013 (CH2)8CH3 31014 cyclopropyl 31015 cyclobutyl 31016 cyclohexyl 31017 Ph 31018 PhCH2 31019 Ph(CH2)2 31020 Ph(CH2)3 31021 PhO(CH2)2 31022 PhCH2OCH2CH2 31023 PhCH2O(C═O)CH2CH2 31024 o-CH3Ph 31025 m-CH3Ph 31026 p-CH3Ph 31027 2,4-(CH3)2Ph 31028 3,5-(CH3)2Ph 31029 2,4,6-(CH3)3Ph 31030 p-CH3OPh 31031 p-CH3CH2OPh 31032 p-CH3(CH2)2OPh 31033 p-FPh 31034 p-ClPh 31035 p-BrPh 31036 p-IPh 31037 p-PhOPh 31038 p-PhCH2OPh 31039 p-NO2Ph 31040 p-CNPh 31041 p-CH3SO2Ph 31042

31043

31044

31045

31046

31047

31048

31049

31050

31051

31052

31053

31054

31055

31056

31057

31058

31059

31060

31061

31062

[0091] TABLE 32

Compound No. R2 32001 CH3 32002 CH2CH3 32003 (CH2)2CH3 32004 CH(CH3)2 32005 (CH2)3CH3 32006 CH2CH(CH3)2 32007 CH(CH3)CH2CH3 32008 C(CH3)3 32009 (CH2)4CH3 32010 (CH2)5CH3 32011 (CH2)6CH3 32012 (CH2)7CH3 32013 (CH2)8CH3 32014 cyclopropyl 32015 cyclobutyl 32016 cyclohexyl 32017 Ph 32018 PhCH2 32019 Ph(CH2)2 32020 Ph(CH2)3 32021 PhO(CH2)2 32022 PhCH2OCH2CH2 32023 PhCH2O(C═O)CH2CH2 32024 o-CH3Ph 32025 m-CH3Ph 32026 p-CH3Ph 32027 2,4-(CH3)2Ph 32028 3,5-(CH3)2Ph 32029 2,4,6-(CH3)3Ph 32030 p-CH3OPh 32031 p-CH3CH2OPh 32032 p-CH3(CH2)2OPh 32033 p-FPh 32034 p-ClPh 32035 p-BrPh 32036 p-IPh 32037 p-PhOPh 32038 p-PhCH2OPh 32039 p-NO2Ph 32040 p-CNPh 32041 p-CH3SO2Ph 32042

32043

32044

32045

32046

32047

32048

32049

32050

32051

32052

32053

32054

32055

32056

32057

32058

32059

32060

32061

32062

[0092] TABLE 33

Compound No. R2 33001 CH3 33002 CH2CH3 33003 (CH2)2CH3 33004 CH(CH3)2 33005 (CH2)3CH3 33006 CH2CH(CH3)2 33007 CH(CH3)CH2CH3 33008 C(CH3)3 33009 (CH2)4CH3 33010 (CH2)5CH3 33011 (CH2)6CH3 33012 (CH2)7CH3 33013 (CH2)8CH3 33014 cyclopropyl 33015 cyclobutyl 33016 cyclohexyl 33017 Ph 33018 PhCH2 33019 Ph(CH2)2 33020 Ph(CH2)3 33021 PhO(CH2)2 33022 PhCH2OCH2CH2 33023 PhCH2O(C═O)CH2CH2 33024 o-CH3Ph 33025 m-CH3Ph 33026 p-CH3Ph 33027 2,4-(CH3)2Ph 33028 3,5-(CH3)2Ph 33029 2,4,6-(CH3)3Ph 33030 p-CH3OPh 33031 p-CH3CH2OPh 33032 p-CH3(CH2)2OPh 33033 p-FPh 33034 p-ClPh 33035 p-BrPh 33036 p-IPh 33037 p-PhOPh 33038 p-PhCH2OPh 33039 p-NO2Ph 33040 p-CNPh 33041 p-CH3SO2Ph 33042

33043

33044

33045

33046

33047

33048

33049

33050

33051

33052

33053

33054

33055

33056

33057

33058

33059

33060

33061

33062

[0093] TABLE 34

Compound No. R2 34001 CH3 34002 CH2CH3 34003 (CH2)2CH3 34004 CH(CH3)2 34005 (CH2)3CH3 34006 CH2CH(CH3)2 34007 CH(CH3)CH2CH3 34008 C(CH3)3 34009 (CH2)4CH3 34010 (CH2)5CH3 34011 (CH2)6CH3 34012 (CH2)7CH3 34013 (CH2)8CH3 34014 cyclopropyl 34015 cyclobutyl 34016 cyclohexyl 34017 Ph 34018 PhCH2 34019 Ph(CH2)2 34020 Ph(CH2)3 34021 PhO(CH2)2 34022 PhCH2OCH2CH2 34023 PhCH2O(C═O)CH2CH2 34024 o-CH3Ph 34025 m-CH3Ph 34026 p-CH3Ph 34027 2,4-(CH3)2Ph 34028 3,5-(CH3)2Ph 34029 2,4,6-(CH3)3Ph 34030 p-CH3OPh 34031 p-CH3CH2OPh 34032 p-CH3(CH2)2OPh 34033 p-FPh 34034 p-ClPh 34035 p-BrPh 34036 p-IPh 34037 p-PhOPh 34038 p-PhCH2OPh 34039 p-NO2Ph 34040 p-CNPh 34041 p-CH3SO2Ph 34042

34043

34044

34045

34046

34047

34048

34049

34050

34051

34052

34053

34054

34055

34056

34057

34058

34059

34060

34061

34062

[0094] TABLE 35

Compound No. R2 35001 CH3 35002 CH2CH3 35003 (CH2)2CH3 35004 CH(CH3)2 35005 (CH2)3CH3 35006 CH2CH(CH3)2 35007 CH(CH3)CH2CH3 35008 C(CH3)3 35009 (CH2)4CH3 35010 (CH2)5CH3 35011 (CH2)6CH3 35012 (CH2)7CH3 35013 (CH2)8CH3 35014 cyclopropyl 35015 cyclobutyl 35016 cyclohexyl 35017 Ph 35018 PhCH2 35019 Ph(CH2)2 35020 Ph(CH2)3 35021 PhO(CH2)2 35022 PhCH2OCH2CH2 35023 PhCH2O(C═O)CH2CH2 35024 o-CH3Ph 35025 m-CH3Ph 35026 p-CH3Ph 35027 2,4-(CH3)2Ph 35028 3,5-(CH3)2Ph 35029 2,4,6-(CH3)3Ph 35030 p-CH3OPh 35031 p-CH3CH2OPh 35032 p-CH3(CH2)2OPh 35033 p-FPh 35034 p-ClPh 35035 p-BrPh 35036 p-IPh 35037 p-PhOPh 35038 p-PhCH2OPh 35039 p-NO2Ph 35040 p-CNPh 35041 p-CH3SO2Ph 35042

35043

35044

35045

35046

35047

35048

35049

350350

35051

35052

35053

35054

35055

35056

35057

35058

35059

35060

35061

35062

[0095] TABLE 36

Compound No. R2 36001 CH3 36002 CH2CH3 36003 (CH2)2CH3 36004 CH(CH3)2 36005 (CH2)3CH3 36006 CH2CH(CH3)2 36007 CH(CH3)CH2CH3 36008 C(CH3)3 36009 (CH2)4CH3 36010 (CH2)5CH3 36011 (CH2)6CH3 36012 (CH2)7CH3 36013 (CH2)8CH3 36014 cyclopropyl 36015 cyclobutyl 36016 cyclohexyl 36017 Ph 36018 PhCH2 36019 Ph(CH2)2 36020 Ph(CH2)3 36021 PhO(CH2)2 36022 PhCH2OCH2CH2 36023 PhCH2O(C═O)CH2CH2 36024 o-CH3Ph 36025 m-CH3Ph 36026 p-CH3Ph 36027 2,4-(CH3)2Ph 36028 3,5-(CH3)2Ph 36029 2,4,6-(CH3)3Ph 36030 p-CH3OPh 36031 p-CH3CH2OPh 36032 p-CH3(CH2)2OPh 36033 p-FPh 36034 p-ClPh 36035 p-BrPh 36036 p-IPh 36037 p-PhOPh 36038 p-PhCH2OPh 36039 p-NO2Ph 36040 p-CNPh 36041 p-CH3SO2Ph 36042

36043

36044

36045

36046

36047

36048

36049

360350

36051

36052

36053

36054

36055

36056

36057

36058

36059

360360

36061

36062

[0096] TABLE 37

Compound No. R2 37001 CH3 37002 CH2CH3 37003 (CH2)2CH3 37004 CH(CH3)2 37005 (CH2)3CH3 37006 CH2CH(CH3)2 37007 CH(CH3)CH2CH3 37008 C(CH3)3 37009 (CH2)4CH3 37010 (CH2)5CH3 37011 (CH2)6CH3 37012 (CH2)7CH3 37013 (CH2)8CH3 37014 cyclopropyl 37015 cyclobutyl 37016 cyclohexyl 37017 Ph 37018 PhCH2 37019 Ph(CH2)2 37020 Ph(CH2)3 37021 PhO(CH2)2 37022 PhCH2OCH2CH2 37023 PhCH2O(C═O)CH2CH2 37024 o-CH3Ph 37025 m-CH3Ph 37026 p-CH3Ph 37027 2,4-(CH3)2Ph 37028 3,5-(CH3)2Ph 37029 2,4,6-(CH3)3Ph 37030 p-CH3OPh 37031 p-CH3CH2OPh 37032 p-CH3(CH2)2OPh 37033 p-FPh 37034 p-ClPh 37035 p-BrPh 37036 p-IPh 37037 p-PhOPh 37038 p-PhCH2OPh 37039 p-NO2Ph 37040 p-CNPh 37041 p-CH3SO2Ph 37042

37043

37044

37045

37046

37047

37048

37049

370350

37051

37052

37053

37054

37055

37056

37057

37058

37059

370360

37061

37062

[0097] TABLE 38

Compound No. R2 38001 CH3 38002 CH2CH3 38003 (CH2)2CH3 38004 CH(CH3)2 38005 (CH2)3CH3 38006 CH2CH(CH3)2 38007 CH(CH3)CH2CH3 38008 C(CH3)3 38009 (CH2)4CH3 38010 (CH2)5CH3 38011 (CH2)6CH3 38012 (CH2)7CH3 38013 (CH2)8CH3 38014 cyclopropyl 38015 cyclobutyl 38016 cyclohexyl 38017 Ph 38018 PhCH2 38019 Ph(CH2)2 38020 Ph(CH2)3 38021 PhO(CH2)2 38022 PhCH2OCH2CH2 38023 PhCH2O(C═O)CH2CH2 38024 o-CH3Ph 38025 m-CH3Ph 38026 p-CH3Ph 38027 2,4-(CH3)2Ph 38028 3,5-(CH3)2Ph 38029 2,4,6-(CH3)3Ph 38030 p-CH3OPh 38031 p-CH3CH2OPh 38032 p-CH3(CH2)2OPh 38033 p-FPh 38034 p-ClPh 38035 p-BrPh 38036 p-IPh 38037 p-PhOPh 38038 p-PhCH2OPh 38039 p-NO2Ph 38040 p-CNPh 38041 p-CH3SO2Ph 38042

38043

38044

38045

38046

38047

38048

38049

380350

38051

38052

38053

38054

38055

38056

38057

38058

38059

380360

38061

38062

[0098] TABLE 39

Compound No. R2 39001 CH3 39002 CH2CH3 39003 (CH2)2CH3 39004 CH(CH3)2 39005 (CH2)3CH3 39006 CH2CH(CH3)2 39007 CH(CH3)CH2CH3 39008 C(CH3)3 39009 (CH2)4CH3 39010 (CH2)5CH3 39011 (CH2)6CH3 39012 (CH2)7CH3 39013 (CH2)8CH3 39014 cyclopropyl 39015 cyclobutyl 39016 cyclohexyl 39017 Ph 39018 PhCH2 39019 Ph(CH2)2 39020 Ph(CH2)3 39021 PhO(CH2)2 39022 PhCH2OCH2CH2 39023 PhCH2O(C═O)CH2CH2 39024 o-CH3Ph 39025 m-CH3Ph 39026 p-CH3Ph 39027 2,4-(CH3)2Ph 39028 3,5-(CH3)2Ph 39029 2,4,6-(CH3)3Ph 39030 p-CH3OPh 39031 p-CH3CH2OPh 39032 p-CH3(CH2)2OPh 39033 p-FPh 39034 p-ClPh 39035 p-BrPh 39036 p-IPh 39037 p-PhOPh 39038 p-PhCH2OPh 39039 p-NO2Ph 39040 p-CNPh 39041 p-CH3SO2Ph 39042

39043

39044

39045

39046

39047

39048

39049

390350

39051

39052

39053

39054

39055

39056

39057

39058

39059

390360

39061

39062

[0099] TABLE 40

Compound No. R2 40001 CH3 40002 CH2CH3 40003 (CH2)2CH3 40004 CH(CH3)2 40005 (CH2)3CH3 40006 CH2CH(CH3)2 40007 CH(CH3)CH2CH3 40008 C(CH3)3 40009 (CH2)4CH3 40010 (CH2)5CH3 40011 (CH2)6CH3 40012 (CH2)7CH3 40013 (CH2)8CH3 40014 cyclopropyl 40015 cyclobutyl 40016 cyclohexyl 40017 Ph 40018 PhCH2 40019 Ph(CH2)2 40020 Ph(CH2)3 40021 PhO(CH2)2 40022 PhCH2OCH2CH2 40023 PhCH2O(C═O)CH2CH2 40024 o-CH3Ph 40025 m-CH3Ph 40026 p-CH3Ph 40027 2,4-(CH3)2Ph 40028 3,5-(CH3)2Ph 40029 2,4,6-(CH3)3Ph 40030 p-CH3OPh 40031 p-CH3CH2OPh 40032 p-CH3(CH2)2OPh 40033 p-FPh 40034 p-ClPh 40035 p-BrPh 40036 p-IPh 40037 p-PhOPh 40038 p-PhCH2OPh 40039 p-NO2Ph 40040 p-CNPh 40041 p-CH3SO2Ph 40042

40043

40044

40045

40046

40047

40048

40049

40050

40051

40052

40053

40054

40055

40056

40057

40058

40059

400360

40061

40062

[0100] TABLE 41

Compound No. R2 Compound No. R2 41001 CH3 41045

41002 CH2CH3 41046

41003 (CH2)2CH3 41047

41004 CH(CH3)2 41048

41005 (CH2)3CH3 41049

41006 CH2CH(CH3)2 41050

41007 CH(CH3)CH2CH3 41051

41008 C(CH3)3 41052

41009 (CH2)4CH3 41053

41010 (CH2)5CH3 41054

41011 (CH2)6CH3 41055

41012 (CH2)7CH3 41056

41013 (CH2)8CH3 41057

41014 cyclopropyl 41058

41015 cyclobutyl 41059

41016 cyclohexyl 41060

41017 Ph 41061

41018 PhCH2 41062

41019 Ph(CH2)2 41020 Ph(CH2)3 41021 PhO(CH2)2 41022 PhCH2OCH2CH2 41023 PhCH2O(C═O)CH2CH2 41024 o-CH3Ph 41025 m-CH3Ph 41026 p-CH3Ph 41027 2,4-(CH3)2Ph 41028 3,5-(CH3)2Ph 41029 2,4,6(CH3)3Ph 41030 p-CH3OPh 41031 p-CH3CH2OPh 41032 p-CH3(CH2)2OPh 41033 p-FPh 41034 p-ClPh 41035 p-BrPh 41036 p-IPh 41037 p-PhOPh 41038 p-PhCH2OPh 41039 p-NO2Ph 41040 p-CNPh 41041 p-CH3SO2Ph 41042

41043

41044

[0101] TABLE 42

Compound No. R2 Compound No. R2 42001 CH3 42045

42002 CH2CH3 42046

42003 (CH2)2CH3 42047

42004 CH(CH3)2 42048

42005 (CH2)3CH3 42049

42006 CH2CH(CH3)2 42050

42007 CH(CH3)CH2CH3 42051

42008 C(CH3)3 42052

42009 (CH2)4CH3 42053

42010 (CH2)5CH3 42054

42011 (CH2)6CH3 42055

42012 (CH2)7CH3 42056

42013 (CH2)8CH3 42057

42014 cyclopropyl 42058

42015 cyclobutyl 42059

42016 cyclohexyl 42060

42017 Ph 42061

42018 PhCH2 42062

42019 Ph(CH2)2 42020 Ph(CH2)3 42021 PhO(CH2)2 42022 PhCH2OCH2CH2 42023 PhCH2O(C═O)CH2CH2 42024 o-CH3Ph 42025 m-CH3Ph 42026 p-CH3Ph 42027 2,4-(CH3)2Ph 42028 3,5-(CH3)2Ph 42029 2,4,6(CH3)3Ph 42030 p-CH3OPh 42031 p-CH3CH2OPh 42032 p-CH3(CH2)2OPh 42033 p-FPh 42034 p-ClPh 42035 p-BrPh 42036 p-IPh 42037 p-PhOPh 42038 p-PhCH2OPh 42039 p-NO2Ph 42040 p-CNPh 42041 p-CH3SO2Ph 42042

42043

42044

[0102] TABLE 43

Compound No. R2 Compound No. R2 43001 CH3 43045

43002 CH2CH3 43046

43003 (CH2)2CH3 43047

43004 CH(CH3)2 43048

43005 (CH2)3CH3 43049

43006 CH2CH(CH3)2 43050

43007 CH(CH3)CH2CH3 43051

43008 C(CH3)3 43052

43009 (CH2)4CH3 43053

43010 (CH2)5CH3 43054

43011 (CH2)6CH3 43055

43012 (CH2)7CH3 43056

43013 (CH2)8CH3 43057

43014 cyclopropyl 43058

43015 cyclobutyl 43059

43016 cyclohexyl 43060

43017 Ph 43061

43018 PhCH2 43062

43019 Ph(CH2)2 43020 Ph(CH2)3 43021 PhO(CH2)2 43022 PhCH2OCH2CH2 43023 PhCH2O(C═O)CH2CH2 43024 o-CH3Ph 43025 m-CH3Ph 43026 p-CH3Ph 43027 2,4-(CH3)2Ph 43028 3,5-(CH3)2Ph 43029 2,4,6(CH3)3Ph 43030 p-CH3OPh 43031 p-CH3CH2OPh 43032 p-CH3(CH2)2OPh 43033 p-FPh 43034 p-ClPh 43035 p-BrPh 43036 p-IPh 43037 p-PhOPh 43038 p-PhCH2OPh 43039 p-NO2Ph 43040 p-CNPh 43041 p-CH3SO2Ph 43042

43043

43044

[0103] TABLE 44

Compound No. R2 Compound No. R2 44001 CH3 44045

44002 CH2CH3 44046

44003 (CH2)2CH3 44047

44004 CH(CH3)2 44048

44005 (CH2)3CH3 44049

44006 CH2CH(CH3)2 44050

44007 CH(CH3)CH2CH3 44051

44008 C(CH3)3 44052

44009 (CH2)4CH3 44053

44010 (CH2)5CH3 44054

44011 (CH2)6CH3 44055

44012 (CH2)7CH3 44056

44013 (CH2)8CH3 44057

44014 cyclopropyl 44058

44015 cyclobutyl 44059

44016 cyclohexyl 44060

44017 Ph 44061

44018 PhCH2 44062

44019 Ph(CH2)2 44020 Ph(CH2)3 44021 PhO(CH2)2 44022 PhCH2OCH2CH2 44023 PhCH2O(C═O)CH2CH2 44024 o-CH3Ph 44025 m-CH3Ph 44026 p-CH3Ph 44027 2,4-(CH3)2Ph 44028 3,5-(CH3)2Ph 44029 2,4,6(CH3)3Ph 44030 p-CH3OPh 44031 p-CH3CH2OPh 44032 p-CH3(CH2)2OPh 44033 p-FPh 44034 p-ClPh 44035 p-BrPh 44036 p-IPh 44037 p-PhOPh 44038 p-PhCH2OPh 44039 p-NO2Ph 44040 p-CNPh 44041 p-CH3SO2Ph 44042

44043

44044

[0104] TABLE 45

Compound No. R2 Compound No. R2 45001 CH3 45045

45002 CH2CH3 45046

45003 (CH2)2CH3 45047

45004 CH(CH3)2 45048

45005 (CH2)3CH3 45049

45006 CH2CH(CH3)2 45050

45007 CH(CH3)CH2CH3 45051

45008 C(CH3)3 45052

45009 (CH2)4CH3 45053

45010 (CH2)5CH3 45054

45011 (CH2)6CH3 45055

45012 (CH2)7CH3 45056

45013 (CH2)8CH3 45057

45014 cyclopropyl 45058

45015 cyclobutyl 45059

45016 cyclohexyl 45060

45017 Ph 45061

45018 PhCH2 45062

45019 Ph(CH2)2 45020 Ph(CH2)3 45021 PhO(CH2)2 45022 PhCH2OCH2CH2 45023 PhCH2O(C═O)CH2CH2 45024 o-CH3Ph 45025 m-CH3Ph 45026 p-CH3Ph 45027 2,4-(CH3)2Ph 45028 3,5-(CH3)2Ph 45029 2,4,6(CH3)3Ph 45030 p-CH3OPh 45031 p-CH3CH2OPh 45032 p-CH3(CH2)2OPh 45033 p-FPh 45034 p-ClPh 45035 p-BrPh 45036 p-IPh 45037 p-PhOPh 45038 p-PhCH2OPh 45039 p-NO2Ph 45040 p-CNPh 45041 p-CH3SO2Ph 45042

45043

45044

[0105] TABLE 46

Compound No. R2 Compound No. R2 46001 CH3 46045

46002 CH2CH3 46046

46003 (CH2)2CH3 46047

46004 CH(CH3)2 46048

46005 (CH2)3CH3 46049

46006 CH2CH(CH3)2 46050

46007 CH(CH3)CH2CH3 46051

46008 C(CH3)3 46052

46009 (CH2)4CH3 46053

46010 (CH2)5CH3 46054

46011 (CH2)6CH3 46055

46012 (CH2)7CH3 46056

46013 (CH2)8CH3 46057

46014 cyclopropyl 46058

46015 cyclobutyl 46059

46016 cyclohexyl 46060

46017 Ph 46061

46018 PhCH2 46062

46019 Ph(CH2)2 46020 Ph(CH2)3 46021 PhO(CH2)2 46022 PhCH2OCH2CH2 46023 PhCH2O(C═O)CH2CH2 46024 o-CH3Ph 46025 m-CH3Ph 46026 p-CH3Ph 46027 2,4-(CH3)2Ph 46028 3,5-(CH3)2Ph 46029 2,4,6(CH3)3Ph 46030 p-CH3OPh 46031 p-CH3CH2OPh 46032 p-CH3(CH2)2OPh 46033 p-FPh 46034 p-ClPh 46035 p-BrPh 46036 p-IPh 46037 p-PhOPh 46038 p-PhCH2OPh 46039 p-NO2Ph 46040 p-CNPh 46041 p-CH3SO2Ph 46042

46043

46044

[0106] The compound numbers described in the above tables correspond to the compound numbers to be described in Examples.

[0107] A description will hereinafter be made about certain representative production processes according to the present invention.

[0108] [Production process of an amino acid N-carboxyanhydride with a substituent on a nitrogen atom thereof, which is represented by the formula (1)]

[0109] The compound represented by the formula (1) can be produced by reacting an amino acid N-carboxyanhydride, which is represented by the formula (4), with a compound of the formula (5) or (6).

[0110] Incidentally, the amino acid N-carboxyanhydride represented by the formula (4), which is used as a raw material in the production of the invention compound represented by the formula (1), can be produced by reacting the corresponding available amino acid with phosgene or by causing phosphorus trichloride, thionyl chloride or the like on an amino acid with a nitrogen atom thereof protected by urethane.

[0111] Further, the compound represented by the formula (5) or (6) is readily available from the market or by synthesis in a known manner.

[0112] The reaction temperature may range from −78 to 200° C., preferably from −50 to 50° C. The reaction time, on the other hand, may range from several minutes to 72 hours, preferably from several minutes to 24 hours.

[0113] [Production process of an amide derivative represented by the formula (8)]

[0114] The amidation reaction according to the present invention can be practiced by dissolving an N-substituted NCA in an inert diluent (for example, ethyl acetate) and then cooling the resulting solution under stirring. As an alternative, the reaction can be conducted in the absence of an inert diluent. Next, a solution of a desired amine (including a protected or unprotected amino acid) in an inert solvent (for example, ethyl acetate) is charged dropwise. This charging of the amine into a reaction system may also be conducted in the absence of an inert diluent. To the mixture so obtained, a base (for example, N-methylmorpholine, 4-dimethylaminopyridine or the like) is added. The base can promote a condensation reaction and can eliminate carbonic acid produced during the reaction, although it is not absolutely necessary to add the base.

[0115] Per mole of the N-substituted NCA, the desired amine may be used in an amount of from 1 to 20 equivalents, preferably from 1 to 5 equivalents, and the base, when to be added, may be used in an amount of from 0.1 to 20 equivalents, preferably from 0.1 to 5 equivalents.

[0116] When the inert diluent is used, the concentration of the N-substituted NCA may range from 0.01 to 50 mol/L, with a range of from 0.05 to 20 mol/L being preferred.

[0117] The reaction temperature may range from −78 to 200° C., preferably from −50 to 50° C. The reaction time, on the other hand, may range from several minutes to 72 hours, preferably from several minutes to 24 hours.

[0118] The amide derivative so completed can be purified by washing it with an aqueous acidic solution (for example, an aqueous solution of hydrochloric acid or an aqueous solution of potassium hydrogensulfate) to remove the unreacted amine, by washing it with an aqueous alkaline solution (for example, an aqueous solution of sodium hydroxide or an aqueous solution of sodium hydrogencarbonate) to eliminate byproducts formed by decomposition or the like, or by an operation such as recrystallization making use of an appropriate solvent. The amide derivative obtained by this purification is extremely uniform, and practically requires no further purification. As the concurrent formation of byproducts is very limited, the amide derivative is formed with extremely high yield and its purification is easy.

[0119] A description will next be described about racemization of an amino acid N-carboxyanhydride with a substituent of the acyl type on a nitrogen atom thereof as described herein. This compound can be readily converted into its corresponding diastereomer compound (diamide compound) by conducting a reaction with an optically active compound. It is possible to confirm racemization of the resulting diastereomer compound, because the surplus rate of the diastereomer can be easily determined by analyzing the compound, for example, by high-performance liquid chromatography, nuclear magnetic resonance spectroscopy or the like. The compounds and production processes described herein have been ascertained to be free of the problem of racemization because each of the compounds can be obtained in the form of a single diastereomer compound (diamide compound) alone by conducting the reaction under appropriate conditions.

[0120] Incidentally, the amine substituted by R³ and R⁴, which is represented by the formula (7) and is used as a raw material in the production of the invention compound represented by the formula (8), is readily available from the market or by synthesis in a known manner.

EXAMPLES

[0121] Examples and Referential Examples of the present invention will hereinafter be described. It should, however, be borne in mind that the present invention is by no means limited by them.

Example 1 Synthesis of (S)-3-benzoyl-4-methyl-2,5-oxazolidinedione (L-N-benzoylalaline-NCA)

[0122]

[0123] (S)-4-Methyl-2,5-oxazolidinedione (L-alanine-NCA) (230 mg, 2.0 mmol) was dissolved in ethyl acetate (23 mL), followed by the addition of benzoyl chloride (365 mg, 2.6 mmol) under ice cooling. Further, a solution of 4-dimethylaminopyridine (318 mg, 2.6 mmol) in ethyl acetate (11 mL) was added dropwise under ice cooling over 20 minutes. After the resulting mixture was stirred as was at 0° C. for 3 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in a mixed solvent consisting of ethyl acetate (5 mL) and hexane (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound as white crystals (351 mg, 80%).

[0124] Melting point: 104.2-105.1° C.(dec.)

[0125]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.74(3H, d, J=6.8 Hz), 5.13(1H, q, J=6.8 Hz), 7.44-7.54(2H, m), 7.61-7.65(1H, m), 7.72-7.75(2H, m).

[0126] IR(KBr)νmax 3379, 3074, 2991, 1865, 1822, 1698 cm⁻¹

Example 2 Synthesis of (S)-3-benzoyl-4-methyl-2,5-oxazolidinedione (L-N-benzoylalaline-NCA) (Compound No. 1017)

[0127] 4-Dimethylaminopyridine (61 mg, 0.5 mmol) and N-methylmorpholine (152 mg, 1.5 mmol) were dissolved in ethyl acetate (15 mL), followed by the addition of (S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA) (230 mg, 2.0 mmol) under ice cooling. Further, a solution of benzoyl chloride (281 mg, 2.0 mmol) in ethyl acetate (7 mL) was added dropwise under ice cooling over 20 minutes. After the resulting mixture was stirred as was at 0° C. for 2 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in a mixed solvent consisting of ethyl acetate (5 mL) and hexane (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound as white crystals (324 mg, 74%).

Example 3 Synthesis of (S)-3-benzoyl-4-isopropyl-2,5-oxazolidinedione (L-N-benzoylvaline-NCA)

[0128]

[0129] Benzoyl chloride (295 mg, 2.1 mmol) was dissolved in ethyl acetate (21 mL), followed by the addition of (S)-4-isopropyl-2,5-oxazolidinedione (L-valine-NCA) (286 mg, 2.0 mmol) under ice cooling. Further, a solution of 4-dimethylaminopyridine (257 mg, 2.1 mmol) in ethyl acetate (11 mL) was added dropwise under ice cooling over 20 minutes. The resulting mixture was allowed to rise as was in temperature from 09. After the mixture was stirred at room temperature for 2 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in a mixed solvent consisting of ethyl acetate (5 mL) and hexane (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound as white crystals (351 mg, 80%).

[0130] Melting point: 124.8-125.9° C. (dec.) ¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.09(3H, d, J=6.8 Hz), 1.26(3H, d, J=7.1 Hz), 2.51(1H, m), 5.09(1H, d, J=3.7 Hz), 7.47-7.52(2H, m), 7.62-7.66(1H, m), 7.74-7.77(2H, m).

[0131] IR(KBr)νmax 2969, 2937, 2879, 1862, 1816, 1694 cm⁻¹

Example 4 Synthesis of (S)-3-benzoyl-4-tert-butyl-2,5-oxazolidinedione (L-N-benzoyl-tert-leucine-NCA) (Compound No. 9017)

[0132]

[0133] In a similar manner as in Example 3, the title compound was obtained as white crystals (341 mg, 65%) by using benzoyl chloride (295 mg, 2.1 mmol), (S)-4-tert-butyl-2,5-oxazolidinedione (L-tert-leucine-NCA)(314 mg, 2.0 mmol), 4-dimethylaminopyridine (257 mg, 2.1 mmol) and ethyl acetate (32 mL).

[0134] Melting point: 127.8-128.9° C.(dec.)

[0135]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.15(9H, s), 5.10(1H, s), 7.52(2H, t, J=8.1 Hz), 7.67(1H,t, J=7.3 Hz), 7.86(2H, dd,J=1.2,8.3 Hz).

[0136] IR(KBr)νmax 2983, 2963, 2876, 1860, 1808, 1704 cm⁻¹

Example 5 Synthesis of (S)-3-benzoyl-4-phenyl-2,5-oxazolidinedione (L-N-benzoylphenylalanine-NCA) (Compound No. 35017)

[0137]

[0138] In a similar manner as in Example 3, the title compound was obtained as white crystals (476 mg, 81%) by using benzoyl chloride (295 mg, 2.1 mmol), (S)-4-phenyl-2,5-oxazolidinedione (L-phenylalanine-NCA)(382 mg, 2.0 mmol), 4-dimethylaminopyridine (257 mg, 2.1 mmol) and ethyl acetate (32 mL).

[0139] Melting point: 125.8-126.4° C. (dec.)

[0140]¹H-N.M.R.(CDCl₃, 400 MHz) δ 3.50(1H, d, J=2.9 Hz), 3.51(1H, d, J=5.6 Hz), 5.36(1H, dd, J=2.9, 5.6 Hz), 7.09-7.11(2H, m), 7.31-7.36(3H, m), 7.39-7.45(4H, m), 7.57-7.60(1H, m).

[0141] IR(KBr)νmax 3070, 3031, 1867, 1786, 1708 cm⁻¹

Example 6 Synthesis of (S)-3-benzoyl-4-benzyloxy-carbonylethyl-2,5-oxazolidinedione (L-N-benzoyl-O-benzylglutamic acid-NCA) (Compound No. 17017)

[0142]

[0143] In a similar manner as in Example 3, the title compound was obtained as white crystals (573 mg, 78%) by using benzoyl chloride (295 mg, 2.1 mmol), (S)-4-benzyloxycarbonylethyl-2,5-oxazolidinedione (L-N-benzoyl-O-benzylglutamic acid-NCA)(527 mg, 2.0 mmol), 4-dimethylaminopyridine (257 mg, 2.1 mmol) and ethyl acetate (32 mL).

[0144] Melting point: 94.5-94.9° C. (dec.)

[0145]¹H-N.M.R.(CDCl₃, 400 MHz) δ 2.47-2.50(2H, m), 2.53-2.63(2H, m), 5.09(1H, d, J=12.0 Hz), 5.14(1H, d, J=12.2 Hz), 5.21(1H, t, J=5.5 Hz), 7.32-7.39(5H, m), 7.43-7.47(2H, m), 7.61(1H, t, J=7.6 Hz), 7.69(2H, dd, J=1.2, 8.1 Hz). IR(KBr)νmax 3258, 3065, 2964, 1869, 1805, 1731, 1701 cm⁻¹

Example 7 Synthesis of (S)-3-(p-methylbenzoyl)-4-methyl-2,5-oxazolidinedione (L-N-(p-methylbenzoyl)-alanine-NCA) (Compound No. 1026)

[0146]

[0147] p-Methylbenzoyl chloride (309 mg, 2.0 mmol) was dissolved in ethyl acetate (5 mL), followed by the addition of (S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA) (230 mg, 2.0 mmol) under ice cooling. Further, a solution of 4-dimethylaminopyridine (244 mg, 2.0 mmol) in ethyl acetate (10 mL) was added dropwise under ice cooling over 20 minutes. After the resulting mixture was stirred as was at 0° C. for 2 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in a mixed solvent consisting of ethyl acetate (5 mL) and hexane (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound (152 mg, 33%) as a colorless clear syrup.

[0148]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.72(3H, d, J=7.1 Hz), 2.44(3H, s), 5.14(1H, q, J=7.1 Hz), 7.29(2H, d, J=8.1 Hz), 7.65(2H, d, J=8.3 Hz).

[0149] IR(KBr)νmax 3278, 2998, 2942, 1853, 1835, 1694 cm⁻¹

Example 8 Synthesis of (S)-3-(p-bromobenzoyl)-4-methyl-2,5-oxazolidinedione (L-N-(p-bromobenzoyl)-alanine-NCA) (Compound No. 1035)

[0150]

[0151] In a similar manner as in Example 7, the title compound (238 mg, 40%) was obtained as a colorless clear syrup by using p-bromobenzoyl chloride (439 mg, 2.0 mmol), (S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA)(230 mg, 2.0 mmol), 4-dimethylaminopyridine (244 mg, 2.0 mmol) and ethyl acetate (15 mL).

[0152]¹H-N.M .R.(CDCl₃, 400 MHz) δ 1.74(3H, d, J=6.8 Hz), 5.13(1H, q, J=6.8 Hz), 7.61(2H, d, J=2.3 Hz), 7.63(2H, d, J=2.3 Hz).

[0153] IR(KBr)νmax 3350, 2998, 2942, 1855, 1840, 1698 cm⁻¹

Example 9 Synthesis of (S)-3-acetyl-4-methyl-2,5-oxazolidinedione (L-N-acetylalanine-NCA) (Compound No. 1001)

[0154]

[0155] (S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA) (345 mg, 3 mmol) was dissolved in ethyl acetate (20 mL), followed by the addition of acetyl chloride (306 mg, 3.9 mmol) under ice cooling. Further, a solution of N-methyl-morpholine (394 mg, 3.9 mmol) in ethyl acetate (10 mL) was added dropwise under ice cooling over 20 minutes. After the resulting mixture was stirred as was at 0° C. for 2 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in chloroform (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound (350 mg, 74%) as a colorless clear syrup.

[0156]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.69(3H, d, J=6.9 Hz), 2.59(3H, s), 4.80(1H, q, J=6.9 Hz).

[0157] IR(neat)νmax 3405, 2945, 1864, 1794, 1720 cm⁻¹

Example 10 Synthesis of (S)-3-acetyl-4-methyl-2,5-oxazolidinedione (L-N-acetylalanine-NCA) (Compound No. 1001)

[0158] (S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA) (345 mg, 3 mmol) was dissolved in ethyl acetate (20 mL), followed by the addition of acetyl chloride (306 mg, 3.9 mmol) under ice cooling. Further, a solution of 4-dimethyl-aminopyridine (476 mg, 3.9 mmol) in ethyl acetate (15 mL) was added dropwise under ice cooling over 20 minutes. After the resulting mixture was stirred as was at 0° C. for 2 hours, a precipitated salt was filtered off, and the filtrate was concentrated under reduced pressure. The concentration residue was re-dissolved in ethyl acetate (5 mL), and insoluble matter was filtered off. The filtrate was concentrated under reduced pressure to afford the title compound (118 mg, 25%) as a colorless clear syrup.

Example 11 Synthesis of (S)-3-decanoyl-4-methyl-2,5-oxazolidinedione (L-N-decanoylalanine-NCA) (Compound No. 1013)

[0159]

[0160] (S)-4-methyl-2, 5-oxazolidinedione (L-alanine-NCA) (345 mg, 3 mmol) was dissolved in ethyl acetate (20 mL), followed by the addition of decanoyl chloride (744 mg, 3.9 mmol) under ice cooling. Further, a solution of N-methylmorpholine (394 mg, 3.9 mmol) in ethyl acetate (10 mL) was added dropwise under ice cooling over 20 minutes, and the resulting mixture was then stirred at the same temperature for 2 hours, the reaction mixture was treated in a similar manner as in Synthesis Process 5 of Example 8 to afford the title compound (525 mg, 65%) as a colorless clear syrup. A portion of the thus-obtained syrup was recrystallized from hexane to obtain white crystals (280 mg).

[0161] Melting point: 61-63° C.

[0162]¹H-N.M.R.(CDCl₃, 400 MHz) δ 0.88(3H, t, J=6.9 Hz), 1.27(12H, bs), 1.68(3H, d, J=7.3 Hz), 1.73-1.60(2H, m), 2.93(2H, t, J=7.6 Hz), 4.81(1H, q, J=7.3 Hz).

[0163] IR(KBr)νmax 2926, 2857, 1868, 1801, 1715 cm⁻¹

Example 12 Synthesis of (S)-3-(3-phenylpropanoyl)-4-methyl-2,5-oxazolidinedione (L-N-(3-phenylpropanoyl)-alanine-NCA) (Compound No. 1019)

[0164]

[0165] (S)-4-methyl-2,5-oxazolidinedione (L-alanine-NCA) (345 mg, 3 mmol) was dissolved in ethyl acetate (20 mL), followed by the addition of 3-phenylpropanoyl chloride (658 mg, 3.9 mmol) under ice cooling. Further, a solution of N-methyl-morpholine (394 mg, 3.9 mmol) in ethyl acetate (10 mL) was added dropwise under ice cooling over 20 minutes, and the resulting mixture was then stirred at the same temperature for 2 hours. The reaction mixture was treated in a similar manner as in Synthesis Process 5 of Example 8 to afford the title compound (408 mg, 55%) as a colorless clear syrup.

[0166]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.64(3H, d, J=6.8 Hz), 3.03-2.99(2H, m), 3.29-3.19(2H, m), 4.78(1H, q, J=6.8 Hz), 7.32-7.18(5H, m).

[0167] IR(neat)νmax 3405, 2910, 2850, 1860, 1803, 1720 cm⁻¹

Example 13 Synthesis of N-benzoyl-L-alanyl-L-phenylalanine methyl ester (Compound No. 30)

[0168]

[0169] L-Phenylalanine methyl ester hydrochloride (518 mg, 2.4 mmol) was suspended in tetrahydrofuran (12 mL), and at 0° C., N-methylmorpholine (242 mg, 2.4 mmol) was added, followed by stirring for 20 minutes. (S)-3-Benzoyl-4-methyl-2,5-oxazolidinedione (N-benzoyl-L-alanine-NCA (438 mg, 2 mmol) was added as crystals at 0° C. After the resulting mixture was stirred for 15 minutes, the mixture was allowed to rise in temperature to room temperature, at which the mixture was stirred for 15 minutes. The reaction mixture was poured into 1 N hydrochloric acid (25 mL), followed by extraction with ethyl acetate (25 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (25 mL) and a saturated aqueous solution of sodium chloride (25 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure. The resulting white solid was washed with hexane-ethyl acetate to afford the title compound (462 mg, 65%) as white crystals.

[0170] Melting point: 134-135° C.

[0171]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.45(3H, d, J=7.0 Hz), 3.05(1H, dd, J=13.9, 6.8 Hz), 3.16(1H, dd, J=13.9, 5.6 Hz), 3.74(3H, s,), 4.71(1H, quintet, J=7.0 Hz), 4.88-4.85(1H, m), 6.78-6.74(2H, m), 7.16-7.06(5H, m), 7.53-7.42(3H, m), 7.77(2H, d, J=7.0 Hz).

[0172] IR(KBr)νmax 3298, 3062, 3025, 2976, 2932, 1741, 1661, 1630, 1536, 1451 cm⁻¹

Example 14 Synthesis of N-benzoyl-L-alanine-(S)-1-(p-tolyl)ethylamide (Compound No. 31)

[0173]

[0174] (S)-3-Benzoyl-4-methyl-2,5-oxazolidinedione (N-benzoyl-L-alanine-NCA) (110 mg, 0.50 mmol) was dissolved in ethyl acetate (2.5 mL), followed by the addition of a solution of (S)-1-(p-tolyl)ethylamine (68 mg, 0.50 mmol) in ethyl acetate (2.5 mL) at 0° C. A solution of N-methylmorpholine (61 mg, 0.6 mmol) in ethyl acetate (3.0 mL) was then added, followed by stirring for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (10 mL), followed by extraction with ethyl acetate (10 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (10 mL) and a saturated aqueous solution of sodium chloride (10 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure to afford the title compound (149 mg, 97%) as white crystals.

[0175] Melting point: 158.6-160.1° C.

[0176]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.46(3H, d, J=7.2 Hz), 1.48(3H, d, J=6.8 Hz), 2.33(3H, s), 4.80 (1H, quintet, J=7.1 Hz), 5.06(1H, quintet, J=7.1 Hz), 7.15(2H, d, J=8.1 Hz), 7.25(2H, d, J=8.1 Hz), 7.40-7.43(1H, m), 7.43(2H, d, J=7.6 Hz), 7.79(2H, d, J=7.6 Hz).

[0177] IR(KBr)ν max 3308, 2978, 2935, 1660, 1639, 1603, 1580, 1527, 1490 cm⁻¹

Example 15 Synthesis of N-benzoyl-L-valine-(S)-1-(p-tolyl)ethylamide (Compound No. 32)

[0178]

[0179] (S)-3-Benzoyl-4-isopropyl-2,5-oxazolidinedione (N-benzoyl-L-valine-NCA) (100 mg, 0.40 mmol) was dissolved in ethyl acetate (2.0 mL), followed by the addition of a solution of (S)-1-(p-tolyl)ethylamine (55 mg, 0.40 mmol) and N-methylmorpholine (61 mg, 0.60 mmol) in ethyl acetate (2.0 mL) at 0° C. The resulting mixture was stirred for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (10 mL), followed by extraction with ethyl acetate (10 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (10 mL) and a saturated aqueous solution of sodium chloride (10 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure to afford the title compound (134 mg, 98%) as white crystals.

[0180] Melting point: 214.4-215.3° C.

[0181]¹H-N.M.R.(CDCl₃, 400 MHz) δ 0.95(3H, d, J=6.6 Hz), 0.96(3H, d, J=6.8 Hz), 1.42(3H, d, J=6.8 Hz), 2.13-2.21(1H, m), 2.33(3H, s), 4.53(1H, dd, J=8.5, 7.3 Hz), 5.06(1H, quintet, J=7.3 Hz), 6.70(1H, brd, J=7.8 Hz), 6.98(1H, brd, J=8.8 Hz), 7.14(2H, d, J=7.8 Hz), 7.21(2H, d, J=8.3 Hz), 7.41(2H, t, J=8.1 Hz), 7.50(1H, t, J=7.5 Hz), 7.79(2H, dd, J=8.1, 1.5 Hz).

[0182] IR(KBr)νmax 3284, 3059, 2970, 2927, 2871, 1654, 1633, 1579, 1541, 1490 cm⁻¹

Example 16 Synthesis of N-benzoyl-L-tert-leucine-(S)-1-(p-tolyl)ethylamide (Compound No. 33)

[0183]

[0184] (S)-3-Benzoyl-4-tert-butyl-2,5-oxazolidinedione (N-benzoyl-L-tert-leucine-NCA)(100 mg, 0.38 mmol) was dissolved in ethyl acetate (2.0 mL), followed by the addition of a solution of (S)-1-(p-tolyl)ethylamine (52 mg, 0.38 mmol) in ethyl acetate (2.0 mL) at 0° C. The resulting mixture was stirred for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (10 mL), followed by extraction with ethyl acetate (10 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (10 mL) and a saturated aqueous solution of sodium chloride (10 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure to afford the title compound (66 mg, 49%) as white crystals.

[0185] Melting point: 144.0-144.8° C.

[0186]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.00(9H, s), 1.43(3H, d, J=6.8 Hz), 2.34(3H, s), 4.51(1H, d, J=9.3 Hz), 5.07(1H, quintet, J=7.3 Hz), 6.38(1H, brd, J=7.6 Hz), 6.96(1H, brd, J=7.0 Hz), 7.14(2H, d, J=7.8 Hz), 7.21(2H, d, J=8.1 Hz), 7.43(2H, t, J=7.8 Hz), 7.51(1H, t, J=7.3 Hz), 7.79(2H, dd, J=8.3, 1.2 Hz).

[0187] IR(KBr)νmax 3274, 3065, 2968, 2872, 1636, 1579, 1525 cm⁻¹

Example 17 Synthesis of N-benzoyl-L-phenylalanine-(S)-1-(p-tolyl)ethylamide (Compound No. 34)

[0188]

[0189] (S)-3-Benzoyl-benzoyl-2,5-oxazolidinedione (N-benzoyl-L-phenylalanine-NCA)(100 mg, 0.34 mmol) was dissolved in ethyl acetate (2.0 mL), followed by the addition of a solution of (S)-1-(p-tolyl)ethylamine (46 mg, 0.34 mmol) in ethyl acetate (2.0 mL) at 0° C. The resulting mixture was stirred for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (10 mL), followed by extraction with ethyl acetate (10 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (10 mL) and a saturated aqueous solution of sodium chloride (10 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure to afford the title compound (110 mg, 84%) as white crystals.

[0190] Melting point: 214.2-214.9° C.

[0191]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.38(3H, d, J=7.1 Hz), 2.34(3H, s,), 3.05(1H, dd, J=13.4, 8.5 Hz), 3.20(1H, dd, J=13.4, 5.6 Hz), 4.82(1H, dt, J=8.3, 5.6 Hz), 4.99(1H, quintet, J=7.2 Hz), 6.03(1H, brd, J=7.8 Hz), 6.96(1H, brd, J=5.9 Hz), 6.98(1H, d, J=8.1 Hz), 7.09(1H, d, J=7.8 Hz), 7.14-7.17(1H, m), 7.18(4H, m), 7.42(2H, dt, J=7.8, 1.2 Hz), 7.50(1H, t, J=7.3 Hz), 7.74(2H, dd, J=8.3, 1.2 Hz).

[0192] IR(KBr)νmax 3289, 3063, 3030, 2974, 2926, 1653, 1632, 1604, 1579, 1541 cm⁻¹

Example 18 Synthesis of N-benzoyl-O-benzyl-L-glutamic acid-(S)-1-(p-tolyl)ethylamide (Compound No. 35)

[0193]

[0194] (S)-3-Benzoyl-4-benzyloxycarbonylethyl-2,5-oxazolidinedione (L-N-benzoyl-O-benzylglutamic acid-NCA)(100 mg, 0.27 mmol) was dissolved in ethyl acetate (2.0 mL), followed by the addition of a solution of (S)-1-(p-tolyl)ethylamine (37 mg, 0.27 mmol) and N-methylmorpholine (28 mg, 0.27 mmol) in ethyl acetate (2.0 mL) at 0° C. The resulting mixture was stirred for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (10 mL), followed by extraction with ethyl acetate (10 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (10 mL) and a saturated aqueous solution of sodium chloride (10 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure to afford the title compound (106 mg, 85%) as white crystals.

[0195] Melting point: 123.4-124.9° C.

[0196]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.43(3H, d, J=7.1 Hz), 2.04-2.23(2H, m), 2.32(3H, s), 2.34-2.67(2H, m), 4.69-4.74(1H, m), 5.00-5.07(1H, m), 5.10(2H, s), 6.85-6.94(1H, m), 7.12(2H, d, J=8.2 Hz), 7.19(2H, d, J=8.2 Hz), 7.29-7.36(6H, m), 7.40-7.45(2H, m), 7.49-7.52(1H, m), 7.80(2H, dd, J=8.3, 1.2 Hz).

[0197] IR(KBr)νmax 3289, 3060, 3032, 2974, 2931, 1726, 1630, 1579, 1534 cm⁻¹

Example 19 Synthesis of N-acetyl-L-alanine-(S)-1-(p-tolyl)ethylamide (Compound No. 36)

[0198]

[0199] (S)-3-Acetyl-4-methyl-2,5-oxazolidinedione (N-acetyl-L-alanine-NCA)(424 mg, 2.7 mmol) was dissolved in ethyl acetate (10 mL), followed by the addition of (S)-1-(p-tolyl)ethylamine (406 mg, 3 mmol) at 0° C. The resulting mixture was stirred for 30 minutes. The reaction mixture was poured into 1 N hydrochloric acid (25 mL), followed by extraction with ethyl acetate (25 mL). The organic layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate (25 mL) and a saturated aqueous solution of sodium chloride (25 mL), and was then dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure, and the resulting white solid was washed with hexane-ethyl acetate to afford the title compound (380 mg, 57%) as white crystals.

[0200] Melting point: 201-203° C.

[0201]¹H-N.M.R.(CDCl₃, 400 MHz) δ 1.32(3H, d, J=7.9 Hz), 1.44(3H, d, J=7.9 Hz), 1.98(3H, s), 2.32(3H, s), 4.54(1H, quintet, J=7.9 Hz), 5.01(1H, quintet, J=7.9 Hz), 6.48(1H, brd, J=7.9 Hz), 6.88(1H, brd, J=7.9 Hz), 7.20-7.10(4H, m).

[0202] IR(KBr)νmax 3292, 1633, 1546, 1444 cm⁻¹

Example 20 Synthesis of N-decanoyl-L-alanyl-L-phenylalanine methyl ester (Compound No. 37)

[0203]

[0204] L-Phenylalanine methyl ester hydrochloride (259 mg, 1.2 mmol) was suspended in tetrahydrofuran (6 mL), followed by the addition of N-methylmorpholine (121 mg, 1.2 mmol) at 0° C. The resulting mixture was stirred for 20 minutes. (S)-3-Decanoyl-4-methyl-2,5-oxazolidinedione (N-decanoyl-L-alanine-NCA) (270 mg, 1 mmol) was added as crystals at 0° C., followed by stirring for 5 minutes. The mixture was allowed to rise in temperature to room temperature, at which the mixture was stirred for 30 minutes. The reaction mixture was treated in a similar manner as in Example 19 to afford the title compound (289 mg, 71%) as white crystals.

[0205] Melting point: 120-122° C.

[0206]¹H-N.M.R.(CDCl₃, 400 MHz) δ 0.88(3H, t, J=6.8 Hz), 1.30-1.25(12H, m), 1.32(3H, d, J=7.1 Hz), 1.61-1.58(2H, m), 2.15(2H, t, J=7.8 Hz), 3.06(1H, dd, J=6.6, 13.9 Hz), 3.14(1H, dd, J=5.6, 13.9 Hz), 3.72(3H, s), 4.50-4.44(1H, m), 4.85-4.80(1H, m), 6.00(1H, brd, J=7.8 Hz), 6.57(1H, brd, J=7.8 Hz), 7.11-7.09(2H, m), 7.30-7.23(3H, m).

[0207] IR(KBr)νmax 3298, 3061, 2923, 2852, 1750, 1644, 1541, 1453 cm⁻¹

Example 21 Synthesis of N-decanoyl-L-alanine-(S)-1-(p-tolyl)ethylamide (Compound No. 38)

[0208]

[0209] (S)-3-Decanoyl-4-methyl-2,5-oxazolidinedione (N-decanoyl-L-alanine-NCA) (100 mg, 0.37 mmol) was dissolved in tetrahydrofuran (3 mL), and at 0° C., (S)-1-(p-tolyl)ethylamine (49 mg, 0.36 mmol) and N-methylmorpholine (37 mg, 0.36 mmol) were added, followed by stirring for 30 minutes. The reaction mixture was treated in a similar manner as in Example 19 to afford the title compound (103 mg, 77%) as white crystals.

[0210] Melting point: 153-154° C.

[0211]¹H-N.M.R.(CDCl₃, 400 MHz) δ 0.88(3H, t, J=6.8 Hz), 1.33-1.20(12H, m), 1.33(3H, d, J=6.8 Hz), 1.44(3H, d, J=6.8 Hz), 1.71-1.59(2H, m), 2.18(2H, t, J=7.2 Hz), 2.33(3H, s), 4.53(1H, quintet, J=6.8 Hz), 5.02(1H, quintet, J=6.8 Hz), 6.28(1H, brs), 6.84(1H, brs), 7.13(2H, d, J=8.1 Hz), 7.20(2H, d, J=8.1 Hz).

[0212] IR(KBr)νmax 3297, 2920, 2852, 1638, 1556, 1452 cm⁻¹

Example 22 Synthesis of N-decanoyl-L-alaninebutylamide (Compound No. 39)

[0213]

[0214] (S)-3-Decanoyl-4-methyl-2,5-oxazolidinedione (N-decanoyl-L-alanine-NCA) (270 mg, 1 mmol) was dissolved in tetrahydrofuran (6 mL), and at 0° C., butylamine (146 mg, 2 mmol) was added, followed by stirring for 30 minutes. The reaction mixture was treated in a similar manner as in Example 19 to afford the title compound (217 mg, 73%) as white crystals.

[0215] Melting point: 128-130° C.

[0216]¹H-N.M.R.(CDCl₃, 400 MHz) δ 0.88(3H, t, J=6.8 Hz), 0.92(3H, t, J=7.3 Hz), 1.36-1.26(14H, m), 1.36(3H, d, J=7.6 Hz), 1.52-1.45(2H, m), 1.63-1.57(2H, m), 2.23-2.15(2H, m), 3.27-3.21(2H, m), 4.51(1H, quintet, J=7.6 Hz), 6.34(1H, brd, J=7.6 Hz), 6.61(1H, brs).

[0217] IR(KBr)νmax 3295, 3096, 2959, 2925, 2853, 1634, 1545, 1468 cm⁻¹

Example 23 Synthesis of N-decanoyl-L-alaninemorpholino-amide (Compound No. 40)

[0218]

[0219] (S)-3-Decanoyl-4-methyl-2,5-oxazolidinedione (N-decanoyl-L-alanine-NCA) (100 mg, 0.37 mmol) was dissolved in tetrahydrofuran (3 mL), and at 0° C., morpholine (52 mg, 0.6 mmol) was added, followed by stirring for 30 minutes. The reaction mixture was treated in a similar manner as in Example 19 to afford the title compound (112 mg, 97%) as a colorless clear syrup.

[0220]¹H-N.M.R.(CDCl₃, 400 MHz) δ 0.88(3H, t, J=6.9 Hz), 1.32-1.19(12H, m), 1.31(3H, d, J=7.8 Hz), 1.64-1.59(2H, m), 2.20(2H, t, J=7.6 Hz), 3.61-3.47(4H, m), 3.73-3.66(4H, m), 4.89(1H, quintet, J=7.8 Hz), 6.60-6.55(1H, m).

[0221] IR(neat)νmax 3308, 2926, 2856, 1637, 1535, 1466 cm⁻¹

INDUSTRIAL APPLICABILITY

[0222] The invention compounds represented by the formula (1) readily react with nucleophilic reagents such as free amines, and use of these compounds permits high-yield, mass and low-cost production of amino acid derivatives, optically active compounds, peptides, polypeptides or the like without racemization. The novel compounds and novel production processes according to the present invention, therefore, are extremely useful and are expected to find themselves as industrially-excellent compounds and processes in many fields led by the fields of pharmaceuticals and agrochemicals. 

1. An amino acid N-carboxyanhydride with a substituent on a nitrogen atom thereof, represented by the following formula (1):

wherein R¹ and R² each independently represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heterocyclic alkyl group:
 2. An amino acid N-carboxyanhydride with a substituent on a nitrogen atom thereof, represented by the following formula (1):

wherein R¹ and R² each independently represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heterocyclic alkyl group, with a proviso that a compound in which R² is a 2-oxopropyl group, a compound of the following formula (2) or a compound of the following formula (3) is excluded.


3. An amino acid N-carboxyanhydride according to claim 1 or 2, wherein R² is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, or a substituted or unsubstituted aralkyl group.
 4. An amino acid N-carboxyanhydride according to claim 1 or 2, wherein R² is a substituted or unsubstituted aryl group.
 5. An amino acid N-carboxyanhydride according to claim 1 or 2, wherein R² is a substituted or unsubstituted heterocycle or a substituted or unsubstituted heterocyclic alkyl group.
 6. An amino acid N-carboxyanhydride according to any one of claims 1-5, wherein R¹ is a side chain on an α-carbon atom of a protected or unprotected amino acid.
 7. A process for the production of an amino acid N-carboxyanhydride with a substituent on a nitrogen atom thereof, said N-carboxyanhydride being represented by the formula (1), which comprises reacting, in an inert diluent and in the presence of a condensing agent, an amino acid N-carboxyanhydride represented by the following formula (4):

wherein R¹ has the same meaning as defined in claim 1 with a compound represented by the following formula (5):

wherein R² has the same meaning as defined in claim
 1. 8. A process for the production of an amino acid N-carboxyanhydride according to claim 1, which comprises reacting, in an inert diluent and in the presence of an amine base, an amino acid N-carboxyanhydride represented by the following formula (4):

wherein R¹ has the same meaning as defined in claim 1 with a compound represented by the following formula (6):

wherein R² has the same meaning as defined in claim 1 and Y represents a halogen atom.
 9. A process for the production of an amide derivative represented by the following formula (8):

wherein R¹ and R² have the same meanings as defined in any one of claims 1-7, and R³ and R⁴ each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heterocyclic alkyl group, which comprises a step of reacting an amino acid N-carboxyanhydride, which has a substituent on a nitrogen atom thereof and is defined in the corresponding one of claims 1-7, with an amine derivative represented by the following formula (7):

wherein R³ and R⁴ have the same meanings as defined above.
 10. A process according to claim 9, which comprises a step of reacting an amino acid N-carboxyanhydride, which has a substituent on a nitrogen atom thereof and is defined in any one of claims 1-6, with a protected or unprotected amino acid. 